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SUMMARY 
 
 
Peroxisomal matrix proteins are synthesized on cytosolic ribosomes and 
transported to the organelle by shuttling receptors. Matrix proteins containing a 
type 1 signal are carried to the peroxisome by PEX5, whereas those harboring a 
type 2 signal are recognized by PEX7 and then transported by a PEX5-PEX7 
complex. The pathway followed by PEX5 during the protein transport cycle has 
been characterized in detail. After binding a cargo protein in the cytosol, PEX5 
interacts with the peroxisomal docking/translocation machinery (DTM). Following 
this docking event, PEX5 gets inserted into the DTM acquiring a transmembrane 
topology, a step that results in the translocation of the cargo protein across the 
organelle membrane and its release into the peroxisomal lumen, all without ATP 
hydrolysis. PEX5 is then extracted from the DTM through a two-step mechanism. 
First, PEX5 is monoubiquitinated at a conserved cysteine (Cys 11 in human 
PEX5); this monoubiquitinated PEX5 species is subsequently dislocated from the 
DTM in an ATP-dependent manner by the two mechanoenzymes, PEX1 and 
PEX6, which compose the receptor export module (REM). Finally, ubiquitin is 
removed from PEX5 probably by a combination of enzymatic and non-enzymatic 
mechanisms. In contrast to the data available for PEX5, not much is known 
regarding mammalian PEX7. The little that is known regarding PEX7 derives 
mainly from studies in yeasts, organisms that possess a different architecture of 
the PEX7-mediated import pathway. In this work we have optimized a previously 
established peroxisomal in vitro import system to study the pathway followed by 
mammalian PEX7 during the PTS2 protein import cycle. We found that PEX7 
reaches the peroxisome in a PEX5L- and PTS2-dependent manner where it 
acquires a protease-protected status. Acquisition of this status occurs upstream of 
the first cytosolic ATP-dependent step, i.e., before ubiquitination of PEX5L. PEX7 
passing through the peroxisome becomes partially exposed to the peroxisome 
matrix milieu suggesting that cargo release occurs at the trans side of the 
peroxisomal membrane. This in vitro system also allowed us to characterize the 
export step of PEX7. Our results show that whenever export of PEX5L is inhibited 
that of PEX7 is also blocked. This suggests that PEX7 exits the organelle through 
the DTM site occupied by PEX5L. Importantly, in vitro imported PEX5L and PEX7 
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display different export kinetics suggesting that their export is uncoupled. 
Additionally, exploring this PEX7 in vitro import/export system, we were able to 
obtain evidence suggesting that PEX7 travelling through the peroxisome is not 
completely released into the peroxisomal matrix. Finally, a putative link between 
cleavage of the PTS2 signal by Tysnd1, the signal processing peptidase, and 
PTS2 cargo-release into the peroxisomal lumen was discarded.  
SUMMARY/RESUMO 
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RESUMO 
 
 
As proteínas da matriz peroxissomal são sintetizadas em ribossomas livres 
no citosol e só depois transportadas para o organelo por receptores solúveis. As 
proteínas matriciais podem conter um sinal de endereçamento peroxissomal do 
tipo 1 (PTS1) sendo reconhecidas e transportadas pelo receptor PEX5, ou podem 
conter um sinal de endereçamento do tipo 2 (PTS2), sendo reconhecidas pelo 
receptor PEX7 e transportadas para o peroxissoma por um complexo PEX5-
PEX7. O percurso seguido pelo receptor PEX5 durante o ciclo de importação de 
proteínas matriciais foi já amplamente descrito. Depois de ligar as proteínas-cargo 
no citosol, o receptor PEX5 interactua com a chamada maquinaria de “docking” e 
translocação (DTM). Após um primeiro passo de acoplagem, a PEX5 insere-se no 
DTM, adquirindo uma topologia transmembranar. Esta inserção resulta na 
translocação da proteína-cargo através da membrana e na sua libertação para o 
lúmen peroxissomal, tudo isto sem necessidade de hidrólise de ATP. A PEX5 é 
então extraída do DTM através de um processo que compreende dois passos. 
Primeiro, a PEX5 é monoubiquitinada numa cisteína conservada (Cys 11 na PEX5 
humana); seguidamente, esta espécie monoubiquitinada é reconhecida e extraída 
do DTM pelas mecano-enzimas PEX1 e PEX6 num processo dependente de 
ATP. Finalmente, a molécula de ubiquitina é removida no citosol por 
desubiquitinases ou por um processo não enzimático. Tudo isto contrasta com o 
pouco que ainda se sabe sobre o receptor PEX7. Os dados  disponíveis provêm 
de estudos em leveduras, organismos nos quais o sistema de importação 
mediado pela PEX7 apresenta uma arquitectura diferente da dos mamíferos. O 
trabalho apresentado nesta tese mostra que o receptor PEX7 só chega ao 
peroxissoma na presença de uma proteína-cargo e do receptor PEX5. Uma vez 
no peroxissoma, o receptor PEX7 adquire uma completa resistência ao 
tratamento com proteases exógenas. A entrada do receptor PEX7, bem como a 
libertação da proteína-cargo para a matriz, ocorre antes do primeiro passo 
dependente de ATP citosólico, ou seja, antes da monoubiquitinação do receptor 
PEX5. Mostramos também que o receptor PEX7, durante a sua passagem pelo 
peroxissoma, expõe pelo menos uma parte da sua cadeia polipeptídica à matriz 
peroxissomal o que sugere fortemente que a libertação da proteína-cargo se dá já 
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depois de atravessada a membrana do peroxissoma. Os dados descritos nesta 
tese sugerem também que a exportação do receptor PEX7 de volta para o citosol 
depende da exportação do receptor PEX5. No entanto, estes dois eventos 
apresentam cinéticas distintas sugerindo que os dois receptores deixam o 
organelo separadamente. Adicionalmente, são fornecidas evidências de que o 
receptor PEX7 nunca é libertado para a matriz do peroxissoma, ficando antes 
retida no DTM até a sua libertação para o citosol. Finalmente, este trabalho 
permitiu-nos também descartar uma possível conexão entre o processamento do 
sinal PTS2 na matriz peroxissomal e a libertação das proteínas PTS2 para a 
matriz peroxissomal. 
 
ABBREVIATIONS 
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ABBREVIATIONS 
 
AAA ATPases associated with diverse cellular activities 
ABC ATP-Binding Cassette 
ACOX1 Acyl-Coenzyme A oxidase 1 
ADHAPS Alkyl-DHAP synthase 
AGT Alanine glyoxylate aminotransferase 
ALDP Adrenoleukodystrophy protein 
AMACR 2-methylacyl-CoA racemase 
BSA Bovine serum albumin 
CHO Chinese hamster ovary 
DBP D-bifunctional protein 
DECR2 2,4-dienoyl-CoA reductase  
DHAP Dihydroxyacetone phosphate 
DHAPAT DHAP acyltransferase 
DTM Docking/translocation module 
DTT Dithiothreitol 
DUB Deubiquitinating enzyme 
E1 Ubiquitin-activating enzyme 
E2 Ubiquitin-conjugating enzyme 
E3 Ubiquitin ligase 
E-64 N-(trans-epoxysuccinyl)-L-leucine 4-guanidinobutylamide 
EDTA Ethylenediamine tetraacetic acid 
ER Endoplasmic reticulum 
FIS1 Fission 1  
GFP Green fluorescent protein 
GSH Glutathione 
GST Gluthathione-S-transferase 
IgG Immunoglobulin G 
MFF Mitochondrial fission factor 
MOPS 4-morpholinepropanesulfonic acid 
mPTS Membrane peroxisomal targeting signal 
NALD Neonatal Adrenoleukodystrophy 
NTP Nucleoside triphosphate 
PAGE Polyacrylamide gel electrophoresis 
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PBDs Peroxisome biogenesis disorders 
PEX Peroxin 
PHYH Phytanoyl-CoA hydroxylase 
PIM Peroxisomal import machinery 
PMP Peroxisome membrane protein 
PMSF Phenylmethylsulfonyl fluoride 
PNS Postnuclear supernatant 
PTS1 Peroxisomal targeting signal 1 
PTS2 Peroxisomal targeting signal 2 
REM Receptor export module 
RING Really interesting new gene 
SCP2 Sterol carrier protein 2 
SCPx Sterol carrier protein x 
SDS Sodium dodecylsulfate 
SEM Buffer containing sucrose, EDTA and MOPS 
SH3 Src homology 3 domain 
TPR Tetratricopeptide repeats 
Tris Tris(hydroxymethyl)aminomethane 
Ub Ubiquitin 
Ub-PEX5 Monoubiquitinated PEX5 
X-ALD X-linked Adrenoleukodystrophy 
WD Tryptophan-aspartate repeat 
ZS Zellweger syndrome 
ZSDs Zellweger spectrum disorders 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   I- INTRODUCTION
I- INTRODUCTION 
12 
 
1. Structure and function of peroxisomes 
 
Peroxisomes are present in virtually all eukaryotic cells. They were first 
described in 1954 as microbodies by Rhodin (1), but their role remained elusive for 
well over a decade. The name “peroxisome” was proposed in 1966 by Christian de 
Duve, when he identified the first peroxisomal enzymes, namely hydrogen 
peroxide-originating oxidases and catalase, an enzyme that catalyses hydrogen 
peroxide disproportionation (2). These organelles are, unlike chloroplasts and 
mitochondria, surrounded by a single phospholipid bilayer membrane and are 
devoided of DNA (3–5).  Their matrix is characterized by high protein 
concentrations. In some organisms and tissues (i.e. liver cells in rodents) some 
proteins are so abundant that they originate electron-dense crystalline structures 
(5–7) (see Figure 1). Peroxisomes are typically spherical organelles with a 
diameter ranging between 0.1 and 1 µm, though their morphology, abundance and 
even function can differ greatly between species, tissue and prevailing 
environmental conditions (reviewed in (8–11)).  
 
 
Figure 1. Electron micrograph of peroxisomes from a rat liver postnuclear 
supernatant. A crystalline inclusion of urate oxidase is marked (►). Micrograph kindly taken 
by Prof. Dr. Manuel Teixeira da Silva, IBMC, Porto, Portugal). 
 
The biochemical plasticity of peroxisomes is so large that, in some 
organisms, specialized forms of this organelle received other designations. For 
instance, peroxisomes in some germinating seed cells are called glyoxysomes 
because they harbor enzymes of the glyoxylate cycle (12), Similarly, trypanosome 
peroxisomes are called glycosomes because they contain part of the glycolysis 
pathway (13). Finally, filamentous ascomycetes (e.g. Neurospora crassa) have 
Woronin bodies.  These organelles are somewhat unusual as their only 
► 
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established function is to plug septal pores in the event of hyphal damage. This 
prevents the loss of cytoplasm and, therefore, contributes to the maintenance of 
cellular integrity (14).  
Despite the great functional variability of peroxisomes (15–17), two 
conserved metabolic pathways are found amongst evolutionary diverse 
organisms. These are the β-oxidation of fatty acids and hydrogen peroxide-
degradation (18–20). In many yeasts/fungi and plants, the fatty acid β-oxidation 
pathway is exclusively localized in peroxisomes (21), whereas in mammalian cells 
this pathway occurs in both peroxisomes and mitochondria (21, 22). The enzymes 
of the peroxisomal β-oxidation pathway are also involved in the synthesis of 
chemical compounds which function as phytohormones in plants, such as 
jasmonates (23) or indol-3-acetic acid (16, 24, 25). Other peroxisome functions 
include the α-oxidation of branched-chain fatty acids in mammals and plants (26, 
27), the main reactions of photorespiration in leaf peroxisomes (28), the final steps 
of penicillin biosynthesis in some filamentous fungi (29), or synthesis of bile acids 
(30) and ether lipids such as plasmalogens in mammals, which constitute more 
than 80% of the phospholipid content of the white matter in the brain and are 
thought to be involved in cell signalling and protection against reactive oxygen 
species (ROS) (31, 32). Peroxisomes are part of a coordinated multi-organelle 
cellular machinery, physically and functionally interacting with other subcellular 
compartments, namely mitochondria and the endoplasmic reticulum (ER) (33–38). 
 
 
2. Peroxisomal Disorders 
 
The importance of peroxisomes in human health and development is 
dramatically illustrated by a group of genetic diseases, the peroxisomal disorders, 
in which peroxisome functions are partially or even completely impaired. These 
diseases are either caused by defects in peroxisomal enzymes/transporters 
(single enzymes deficiencies) or by mutations in genes encoding peroxins, 
proteins that are specifically required for peroxisome maintenance and inheritance 
(the peroxisomal biogenesis disorders; PBDs, reviewed in (39–42)) 
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2.1. Single enzyme deficiencies 
 
The single peroxisomal enzyme deficiencies can be divided into distinct 
subgroups based on the affected peroxisomal metabolic pathway. They 
encompass single defects in peroxisomal ß-oxidation, plasmalogen biosynthesis 
and α-oxidation, among others (see Table 1). The most prevalent single enzyme 
deficiency is X-linked adrenoleukodystrophy (X-ALD), a progressive 
neurodegenerative disorder caused by defects in ALDP (a peroxisomal membrane 
protein of the ATP-Binding Cassette (ABC) family of transporter proteins) (43–45). 
This deficiency results in the accumulation of very long chain fatty acids in plasma 
and tissues and leads to the progressive demyelination of the central nervous 
system (reviewed in (46)). 
 
Table 1. Peroxisomal single enzyme deficiencies. 
Peroxisomal 
pathway affected 
Peroxisomal disease Enzyme defect 
Ether 
phospholipid 
synthesis 
Rhizomelic chondrodysplasia punctata Type 2 
(DHAPAT deficiency) 
DHAP acyltransferase 
(DHAPAT) 
Rhizomelic chondrodysplasia punctata Type 3 
(alkyl-DHAP synthase deficiency) 
Alkyl-DHAP synthase 
(ADHAPS) 
Peroxisomal  
β-oxidation 
X-linked adrenoleukodystrophy (ALDP deficiency) 
Adrenoleukodystrophy protein 
(ALDP) 
Acyl-CoA oxidase deficiency  Acyl-COA oxidase-1 (ACOX1) 
D-bifunctional protein deficiency D-Bifunctional protein (DBP) 
2-MethylacylCoA racemase deficiency 
2-MethylacylCoA racemase 
(AMACR) 
Sterol carrier protein X deficiency Sterol carrier protein X (SCPx) 
Peroxisomal  
α-oxidation 
Refsum disease (phytanoyl-CoA hydroxylase 
deficiency) 
Phytanoyl-CoA hydroxylase 
(PHYH) 
Glyoxylate 
detoxification 
Hyperoxaluria Type 1 (AGT deficiency) 
Alanine:glyoxylate 
aminotransferase (AGT) 
H2O2-metabolism Acatalasaemia (CAT deficiency) Catalase (CAT) 
Bile acid 
synthesis 
Bile acid-CoA:amino acid N-acyltransferase 
deficiency  
Bile acid-CoA:amino acid N-
acyltransferase (BAAT) 
Adapted from (40) 
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2.2. Peroxisomal biogenesis disorders 
  
Peroxisomal biogenesis disorder (PBDs) are caused by mutations in PEX 
genes (47, 48). These genes encode many of the proteins required for peroxisome 
biogenesis, maintenance and inheritance, the so-called “Peroxins” (see below). 
Contrary to the single enzyme deficiencies, where only one metabolic pathway is 
affected, PBDs result in the loss of several, sometimes all, peroxisomal functions 
and, in some cases, in the complete absence of the organelle (reviewed in (47–
49)).  
The PBD group comprises the Zellweger syndrome (ZS), neonatal 
adrenoleukodystrophy (NALD), infantile Refsum disease (IRD) and rhizomelic 
chondrodysplasia punctata (RCDP) type 1. After the discovery that mutations in 
the same gene could lead to any of the first three conditions, they are presently 
collectively called the Zellweger spectrum disorders (ZSDs) that constitute a triad 
of overlapping disorders with ZS being the most severe, followed by NALD and 
IRD (48). Liver disease, variable neurodevelopment delay, retinopathy, and 
perceptive deafness with onset in the first months of life are clinical symptoms 
common to all three. In addition, patients with ZS are severely hypotonic at birth 
and have distinct facial features, peri-articular calcifications, severe brain 
dysfunction associated with neuronal migration defects and generally, the child 
does not survive past the first year (50). Patients with NALD have hypotonia, 
seizures, progressive white matter disease, and usually die in late infancy (42, 51). 
Patients with IRD may have external features reminiscent of ZS, but no neuronal 
migration disorder and no progressive white matter disease. The cognitive and 
motor development vary between a severe global handicap and moderate learning 
disabilities with deafness and visual impairment, due to retinopathy (26, 42, 52). 
The Zellweger spectrum disorders have been associated with mutations in 
13 different genes. Twelve of these genes encode peroxins involved in protein 
import to the peroxisomal matrix and membrane; severe mutations in these genes 
lead to the impairment of most, if not all, peroxisomal functions (39, 47, 53). 
Recently, a novel and milder form of the disease was identified, Interestingly, the 
only patient identified to date with this disease lacked the common biochemical 
indicators of a ZSD (54). Instead, immunofluorescence microscopy revealed 
abnormalities in peroxisome morphology: Peroxisomes were elongated or 
I- INTRODUCTION 
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enlarged and frequently arranged in rows which suggested a fission defect. 
Indeed, the genetic defect was found to be a homozygous point mutation in 
PEX11β, a gene involved in peroxisome division/proliferation (see section 3.1).  
RCDP type 1 is clinically quite different from the Zellweger spectrum 
disorders although there are some shared features, including the cranial, facial 
(broad low nasal bridge, high arched palate, and dysplastic external ears), and 
ocular abnormalities. It is characterized by the shortening of the proximal bones, 
stippled epiphyses, and by growth and mental retardation (55–57). Besides the 
clinical differences, their genetics is also very distinct. While the ZSD can be 
caused by mutations in any of 13 genes referred to above, RCDP type 1 is 
attributed to mutations in a single gene, the PEX7 gene (55, 57), disrupting only 
the function of a smaller subset of matrix proteins, those containing a peroxisomal 
targeting signal type 2 (see below). 
 
         Table 2. PEX gene defects and clinical phenotypes in PBDs. 
Gene Phenotype Pathway affected 
PEX1 ZS, NALD, IRD Matrix protein import (Receptor recycling) 
PEX2 ZS, IRD Matrix protein import (Receptor recycling) 
PEX3 ZS Membrane protein import 
PEX5 ZS, NALD Matrix protein import 
PEX6 ZS, NALD Matrix protein import (Receptor recycling) 
PEX7 RCDP type1 Matrix protein import 
PEX10 ZS, NALD Matrix protein import (Receptor recycling) 
PEX11β mild ZSD Peroxisome proliferation/division 
PEX12 ZS, NALD, IRD Matrix protein import (Receptor recycling) 
PEX13 ZS, NALD Matrix protein import (Docking/Translocation) 
PEX14 ZS Matrix protein import (Docking/Translocation) 
PEX16 ZS Membrane protein import 
PEX19 ZS Membrane protein import 
PEX26 ZS, NALD, IRD Matrix protein import (Receptor recycling) 
          Adapted from (47, 49, 58). 
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3. Peroxisome biogenesis 
 
As previously mentioned, many of the proteins required for peroxisome 
biogenesis are encoded by the so-called PEX genes and are commonly 
designated by peroxins. They are referred to as PEXn, where n is a number that 
reflects the chronological order of their discovery. Presently, more than 30 
peroxins have been identified in the several organisms used to study peroxisome 
biology (Table 3). However, the number of PEX proteins phylogenetically 
conserved is much lower. In mammals, for instance, only 16 peroxins are 
presently known. Despite this phylogenetic variability, it is now evident that the 
basic aspects of peroxisome biogenesis have been well conserved throughout 
evolution (59–61). Peroxins are involved in three key stages of peroxisome 
biogenesis, namely, import of peroxisomal membrane proteins, import of 
peroxisomal matrix proteins and peroxisomal proliferation, as detailed below. 
 
 
3.1. Origin and maintenance of the peroxisomal membrane 
 
The origin of the peroxisomal membrane has always been a matter of much 
debate in the field (62, 63). The initial structural studies, based on electron 
microscopy, suggested that peroxisomes were generated by budding from the ER 
(63, 64). However, subsequent biochemical data have shown that several 
peroxisomal membrane proteins (PMPs) are synthesized on free ribosomes in the 
cytosol and posttranslationally imported into pre-existing peroxisomes (8, 65, 66), 
an observation behind the classic “growth and division model” according to which 
peroxisomes arise solely by fission and subsequent growth of the pre-existent 
organelle. Nevertheless, considering that most membrane lipids are synthesized in 
the ER, there is little doubt that this organelle participates in the biogenesis of the 
peroxisomal membrane. In fact, the lipid composition of the peroxisomal 
membrane resembles that of the ER, being mostly comprised of 
phosphatidylcholine and phosphatidylethanolamine (67). Although several 
researchers in the field continue to propose that pre-peroxisomal vesicles are 
generated by a budding mechanism out of the ER (68–71), much of the data 
supporting this perspective has been recently questioned ((72); see also below). 
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Furthermore, there are data suggesting that the “ER-to-peroxisome” lipid transport 
occurs not through vesicular trafficking, but rather through close physical contact 
between both organelles, a finding again supporting the growth and division model 
(73–77).  
 
Table 3. Proteins implicated in peroxisomal biogenesis (peroxins).  
 PEX protein Localization Organism Properties / Functions 
Matrix protein 
import 
PEX1 Cyt / Memb M, P, F, Y Receptor export; AAA ATPase  
PEX2 Memb M, P, F, Y E3; RING zing-binding domain 
PEX4 Memb/Cyt P, F, Y E2 
PEX5 Cyt / Memb M, P, F, Y PTS1 and PTS2 targeting; IDD, TPRs 
PEX6 Cyt / Memb M, P, F, Y Receptor export; AAA ATPase 
PEX7 Cyt / Memb M, P, F, Y PTS2 targeting; adaptor protein; WD repeats 
PEX8 Matrix/ Memb F, Y   
PEX10 Memb M, P, F, Y E3; RING zing-binding domain 
PEX12 Memb M, P, F, Y E3; zing-binding domain 
PEX13 Memb M, P, F, Y SH3 
PEX14 Memb M, P, F, Y Coiled-coil 
PEX15 Memb F, Y  PEX1/PEX6 membrane anchor 
PEX17 Memb Y Coiled-coil 
PEX18 Cyt / Memb Y PTS2 targeting 
PEX20 Cyt / Memb F, Y PTS2 targeting 
PEX21 Cyt / Memb Y PTS2 targeting 
PEX22 Memb P, F, Y PEX4 membrane anchor 
PEX26 Memb M, F, Y PEX1/PEX6 membrane anchor 
PEX33 Memb F Coiled-coil 
     
Membrane 
protein import 
PEX3 Memb M, P, F, Y  
PEX16 Memb M, P, F, Y  
PEX19 Cyt / Memb M, P, F, Y PMP targeting; Farnesylation motif 
     
 
Proliferation 
and 
inheritance 
PEX11 Memb M, P, F, Y  
PEX23 Memb F, Y Dysferlin 
PEX24 Memb F, Y  
PEX25 Memb Y  
PEX27 Memb Sc  
PEX28 Memb Sc  
PEX29 Memb Y  
PEX30 Memb Sc Dysferlin 
PEX31 Memb Sc Dysferlin 
PEX32 Memb Y Dysferlin 
PEX34 Memb Sc  
 
Adapted from (78). Mammalian peroxins are highlighted in blue and bold. Abbreviations: Cyt, 
cytosol; Memb, membrane; M, mammals; P, plants; F, fungi; Y, yeast; Sc, S. cerevisiae; PTS1, 
peroxisomal targeting signal 1; PTS2, peroxisomal targeting signal 2; IDD, intrinsic disordered 
domain; TPRs, tetratricopeptide repeats; WD, Tryptophan-aspartate repeat; SH3, Src homology 3; 
RING, really interesting new gene; E3, ubiquitin ligase; Ub, ubiquitin; AAA, ATPases associated 
with diverse cellular activities; E2, ubiquitin-conjugation enzyme; PMP, peroxisomal membrane 
protein. 
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Many of the components that constitute the peroxisome proliferation, 
elongation and fission machinery have already been identified in mammals, yeast 
and plants (79–85). Chief among these is PEX11, one of the first elements of this 
machinery to be described, and one that is present in all eukaryotic organisms (86, 
87). In mammals there are three isoforms of this peroxin, each encoded by a 
different gene (83, 88, 89): PEX11α whose expression is induced by peroxisome 
proliferating agents (response to external stimuli) (61, 90), PEX11β and PEX11γ 
which are constitutively expressed and thought to be responsible for the 
constitutive peroxisomal division (91, 92). PEX11 was shown to have the ability to 
reshape and elongate the peroxisomal membrane (93–95). Furthermore, PEX11 
also seems to take part in the recruitment of other components of the peroxisomal 
fission machinery (96). In yeast, where there is only one PEX11 gene, other 
structurally related peroxins, such as PEX25 and PEX27, come into play (97–99). 
Interestingly, peroxisome share part of the fission machinery with 
mitochondria (90, 100–103). The division of peroxisomal membranes requires the 
dynamin-related protein DLP1, a self-assembling GTPase with mechano-chemical 
properties known to tubulate and constrict membranes (92, 104, 105). Additionally, 
the membrane adaptors, Fission1 (FIS1) and the mitochondrial fission factor 
(MFF) were also found in peroxisomes. These proteins are believed to act as 
recruiting factors for DLP1 (100, 106, 107).  
 
3.1.1. Import of peroxisomal membrane proteins 
 
The machinery that targets newly synthesized peroxisomal membrane 
proteins (PMPs) to the organelle is completely different from the one sorting matrix 
proteins (see section 3.2). The first observation leading to this conclusion was the 
fact that in cells where the import of matrix proteins is defective, one could still find 
peroxisomal ghosts, i.e. membrane vesicles that although devoided of their matrix 
content, still possessed all peroxisomal membrane proteins (41, 108, 109). The 
import machinery of PMPs appears to comprise only 2, perhaps 3, peroxins. 
These are PEX19, PEX3 and, in some organisms, also PEX16 (110–114). PEX19 
is a soluble protein capable of interacting with a broad variety of newly synthesized 
PMPs via their membrane peroxisomal targeting signal (mPTS) (115–120). It is 
currently believed that PEX19 acts as a chaperone for newly synthesized PMPs, 
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shielding their hydrophobic surfaces in the cytosol thus preventing aggregation 
(121). PEX19 also acts as the PMP import receptor, directing them to the 
peroxisomal membrane (115, 116, 122–125). PEX3 is thought to work as a 
membrane recruitment factor for cargo-loaded PEX19 (126–128). In fact, PEX3 
has a higher affinity for cargo-loaded PEX19 than for PEX19 alone (128). It is 
possible that insertion of the PMP into the peroxisomal membrane is promoted by 
PEX3. Indeed, there are some data suggesting that the PEX19-interacting domain 
of PEX3 which is exposed to the cytosol, also interacts with membrane lipids, an 
interaction that is modulated by PEX19 itself (129). Interestingly, the peroxisomal 
targeting of PMPs into the organelle membrane does not require ATP, suggesting 
that the thermodynamic driving force for the whole process may derive from the 
insertion of the PMP into the peroxisomal lipid bilayer (65, 128).  
The role of PEX16 remains vastly unknown. Whereas mutation of the 
corresponding gene seems to lead to the absence of peroxisomal vesicles in some 
organisms (i.e. mammals (110)), in others, no marked effect could be observed 
(130, 131). In yeasts, with the exception of Yarrowia lipolytica, PEX16 orthologs 
have yet to be found (132). 
 Interestingly, cell lines/yeast strains lacking PEX3 or PEX19, in which 
peroxisomal membrane vesicles are seemingly absent (111, 112, 114, 133), are 
capable of generating peroxisomes after a functional copy of the corresponding 
gene is reintroduced (112, 113). These findings led to the belief that in addition to 
the fission of mature organelles there is also de novo synthesis of peroxisomes. 
Furthermore, there is some evidence suggesting that the integral peroxisomal 
membrane protein PEX3 is sorted to the peroxisomal membrane through the ER 
(134–136), an observation that has also been interpreted as evidence supporting 
the ER as the origin of the peroxisomal membrane and not just as a supplier of 
components to pre-existing peroxisomes. Recently, however, new data was found 
contradicting some of these earlier findings. It was shown that yeast cells lacking 
PEX3, already contain vesicular structures that harbour components of the 
docking/translocation machinery, PEX13 and PEX14, among a few other 
peroxisomal proteins. Additionally, when PEX3 was re-introduced, this peroxin 
was sorted, not through the ER, but directly to these vesicular structures, which 
subsequently mature into normal peroxisomes (72). Clearly, the data regarding the 
de novo formation of peroxisomes are to be interpreted with great caution and the 
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physiological relevance of this process and its overall contribution to peroxisomal 
dynamics in normal cells remain to be determined (71, 137–139).  
 
3.2. Matrix protein import 
 
Peroxisomes do not contain DNA and, as such, all peroxisomal matrix 
proteins are encoded in the nucleus, synthesized on cytosolic ribosomes and 
posttranslationally imported peroxisomes. The majority of peroxins (10 out of 16 
peroxins present in mammals) are components of the peroxisomal matrix protein 
import machinery (PIM). Collectively these proteins ensure the correct delivery of 
newly synthesized proteins to the organelle lumen. Most mammalian PIM peroxins 
are part of one of two functional/structural units: PEX13, PEX14, and the “Really 
Interesting New Gene” (RING) peroxins PEX2, PEX10, and PEX12 compose the 
membrane-embedded docking/translocation module (DTM; (140–142)); the two 
peroxisomal “ATPases associated with diverse cellular activities” (AAA ATPases), 
PEX1 and PEX6, together with their peroxisomal membrane anchor, PEX26, 
comprise the receptor export module (REM; (143, 144)). The peroxisomal protein 
shuttling receptors PEX5 and PEX7 complete the list of mammalian peroxins that 
integrate the PIM (55, 145, 146). In addition to these peroxins, the mammalian 
PIM also comprises other proteins, which are mostly involved in 
ubiquitination/deubiquitination events (see below). Due to the fact that their 
function is not restricted to the PIM they are not classified as peroxins. 
 The mammalian peroxins referred to above have orthologs in all 
peroxisome-containing organisms characterized so far, from yeasts and fungi to 
plants (60, 61). Strikingly, however, the reverse is not true. Indeed, several 
peroxins found in plants and lower eukaryotes do not exist in mammals. 
Apparently, evolution led to simpler PIMs. At least two different mechanisms seem 
to be behind this simplification. In one case, the function of two yeast/fungi/plant 
peroxins, PEX4 and PEX22, ended up being carried out by a family of mammalian 
ubiquitin-conjugating enzymes (E2D1/2/3) involved in many other pathways (147). 
In another case, a peroxin (PEX5) acquired the capacity to perform two different 
tasks (import of both PTS1- and PTS2-containing proteins; see below) (148–151), 
each of which is performed by a different peroxin in yeasts/fungi (see (152), and 
references cited therein). Despite these differences, the basics of the mechanism 
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of protein import into the peroxisomal matrix remained relatively well conserved 
during evolution (16, 153–156). 
 
3.2.1. The PEX5-mediated peroxisomal matrix protein import pathway 
 
The import pathway of newly synthesized proteins into the matrix of the 
organelle is generally described using a PEX5-centered perspective comprising 8 
different stages/sub-stages (see Figure 2): First, free PEX5 (stage 0 PEX5) binds 
newly synthesized peroxisomal matrix proteins in the cytosol originating “stage 1a 
PEX5”; the receptor-cargo complex then docks at DTM (stage 1b). This interaction 
ultimately results in the insertion of PEX5 into the DTM (stage 2 PEX5), with the 
concomitant translocation of the cargo into the peroxisomal lumen; PEX5 is then 
monoubiquitinated (stage 3a PEX5) and consequently recognized by the receptor 
export module (stage 3b PEX5). Monoubiquitinated PEX5 is then extracted from 
the DTM (stage 4a PEX5). Finally, after release into the cytosol, 
monoubiquitinated PEX5 (stage 4b PEX5) is deubiquitinated, thus freeing PEX5 
for another round of import (stage 0 PEX5). Interestingly, the steps that culminate 
in the translocation of the cargo protein across the peroxisomal membrane occur 
all in an ATP-independent manner. In contrast, the steps necessary to reset this 
protein transportation system require ATP consumption. A detailed description of 
each one of these steps is presented below. 
 
Cargo recognition by the shuttling receptors PEX5 and PEX7 
Peroxisomal matrix proteins are targeted to the organelle because they 
possess one of two types of peroxisomal targeting signals (PTS). The vast 
majority of them harbor a PTS type 1 (PTS1), a tripeptide with the sequence S-K-
L, or a conserved variant, present at their extreme C termini (157, 158). A few 
peroxisomal matrix proteins possess instead a PTS2. This is an N-terminal 
degenerated nonapeptide with the consensus sequence (R/K)-(L/V/I)-X5-(H/Q)-
(L/A) (159–161). In mammals, only four proteins harboring a PTS2 have been 
identified, while in plants, PTS2-containing proteins may comprise up to one third 
of all peroxisomal matrix proteins (162). For some organisms (e.g. Caenorhabditis 
elegans, (163, 164)), this PTS2-mediated import is even completely absent. In 
contrast to the PTS1, which remains intact upon import, the PTS2 is generally 
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cleaved in the peroxisomal matrix of higher eukaryotes by a serine protease 
(Tysnd1 in mammals and DEG15 in plants) (165–167).  
 In mammals, plants and many other organisms, all peroxisomal matrix 
proteins are transported to the peroxisome by PEX5 (148–151). PEX5 is a 70-kDa 
monomeric protein which in vivo displays a dual subcellular localization, 
peroxisomal and cytosolic, reflecting its role as a shuttling receptor (168–170). 
Structurally, PEX5 comprises two domains (see Figure 3): 1) a natively unfolded 
N-terminal half that contains the binding site for PEX7, a highly conserved cysteine 
residue, and several pentapeptide diaromatic repeats (WXXXF/Y) necessary for a 
productive interaction with the DTM (148, 171–173); and 2) a structured C-terminal 
half possessing seven tetratricopeptide repeats (TPRs) domains that constitute the 
PTS1-binding site (174).  
 Interestingly, binding of PEX5 to newly synthesized matrix proteins that are 
oligomeric in their native state strongly inhibits their oligomerization, suggesting 
that PEX5 is also a chaperone/holdase (175). This property is probably crucial to 
avoid premature oligomerization in the cytosol of proteins that no longer expose 
their PTS1 upon oligomerization (176, 177). The interaction between PEX5 and 
PTS1 proteins is direct and sufficient to ensure that these proteins are efficiently 
targeted to the organelle. The interaction involves the PTS1 peptide on one side, 
and the TPR domains of PEX5 on the other, but the N-terminal half of PEX5 also 
contributes for the interaction (148, 175, 178–180). The interaction between PEX5 
and PTS2-containing proteins requires PEX7, the cytosolic receptor that 
recognizes the PTS2 and serves as an adaptor for the PEX5-mediated import of 
PTS2 proteins (148–151). It is important to note that not all PEX5 molecules can 
drive import of PTS2 proteins. In mammals, the PEX5 transcript undergoes 
alternative spicing to originate two major isoforms (148): the larger isoform of 
PEX5 (PEX5L), which seems to be predominantly expressed (172), and a smaller 
isoform (PEX5S), which lacks a 37-amino acid long insert that contributes for 
PEX7 binding. PEX5S is therefore unable to interact with this receptor and 
consequently unable to import PTS2 proteins. 
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Figure 2. The PEX5-mediated import pathway. 
Using a PEX5-centered in vitro import system, five different populations of PEX5 could be 
detected (stages 0 to 4, substages “a” and “b” are mostly of conceptual nature). Peroxisomal 
matrix cargo proteins (CP) are recognized by free cytosolic PEX5 [stage 0 PEX5]. The 
receptor-cargo protein complex [stage 1a PEX5] docks at the peroxisomal membrane 
docking/translocation machinery yielding stage 1b PEX5. The strong protein-protein 
interactions established between the receptor and DTM components result in the insertion of 
the receptor into the DTM [stage 2 PEX5] and the concomitant translocation and release of 
the cargo protein into the organelle matrix. The receptor is then monoubiquitinated at a 
conserved cysteine residue [stage 3 PEX5], and extracted back to the cytosol by the ATP-
dependent receptor export module (REM) originating monoubiquitinated PEX5 in the cytosol 
[stage 4 PEX5]. Finally, the ubiquitin moiety is rapidly removed by a combination of 
enzymatic (DUBs) and non-enzymatic steps (e.g., by nucleophiles such as glutathione, 
GSH) yielding once again free PEX5 [stage 0 PEX5] that can now undergo another import 
cycle. A control mechanism may act on receptors that become jammed at the DTM. These 
receptors are polyubiquitinated, extracted and degraded via the ubiquitin-proteasome 
pathway (UPS). 
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 PEX7 is a 35-kDa soluble protein of the WD40 repeat family (160, 181, 
182). Its structure comprises six WD repeats (~40 amino acids motifs, containing a 
Trp(W)-Asp(D) dipeptide) that fold into a four-stranded antiparallel β-sheet domain 
(see figure 3). Although the N-terminal region of PEX7 lacks sequence similarity 
with other WD40 domains, it assumes a similar structure. PEX7 thus folds into a 
seven-bladed beta-propeller in a circularised structure, typical of many WD-repeat 
proteins (183). Early experiments aiming at defining the subcellular localization of 
PEX7 gave contradicting results, apparently depending on how the protein was 
epitope-tagged. In general, PEX7 with a tag at the N terminus was predominantly 
cytosolic (55, 181), while PEX7 with a COOH-terminal tag was localized to the 
peroxisome (182). Subsequent success in raising antibodies against PEX7 
allowed an analysis of the endogenous protein. It was found that PEX7 is mainly 
cytosolic but a small fraction of the protein is also present in the peroxisome (184–
186). This dual subcellular localization in vivo suggested that PEX7, like PEX5, 
functions as a shuttling receptor for newly synthesized PTS2 containing proteins. 
In lower eukaryotes, PEX5 does not interact with PEX7, and therefore the 
receptor function of PEX5 is restricted to PTS1 proteins. In these organisms, 
targeting of PTS2 proteins is ensured by a species-specific co-receptor (PEX20, 
PEX18 or PEX21) which displays structural/functional similarities with the N-
terminal half of mammalian PEX5, including the conserved cysteine residue and 
the capacity to interact with PEX7 and PEX14 (152, 160, 187–189).  
 Strikingly, a few peroxisomal matrix proteins lack either one of these PTSs 
but are nonetheless targeted to the organelle by PEX5. In some cases, these 
proteins seem to rely on some ill-defined internal PTSs that are recognized by the 
N-terminal half of PEX5 (179). It has also been suggested that these proteins may 
be imported “piggybacking” with other proteins that do harbor a peroxisomal 
targeting signal (190–193).     
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Figure 3. Structure of mammalian PEX5L and PEX7. 
Schematic representation of PEX5L. IDD, intrinsically disordered domain. The N-terminally 
conserved cysteine is shown (cys); red bars indicate the diaromatic motifs (WXXXF/Y); the 
yellow, grey and blue boxes represent the seven TPR domains. The brown box indicates the 
PEX7 binding site that is present only in the large isoform of PEX5.  Protein structure model 
of PEX5 taken from (174) (PDB: 1FCH). Schematic representation of PEX7. Orange boxes 
indicate the six WD repeats; Crystal structure of yeast PEX7 (PDB: 3W15, (183)).     
 
 
 Docking and translocation of the receptor-cargo complex into the DTM 
and cargo release 
Following cargo recognition, PEX5 interacts with the DTM. Of the DTM 
constituents, PEX13 and PEX14 are the most likely candidates to mediate this 
step (see ref. (194, 195)). Further characterization of the docking step showed that 
it could occur even at low temperatures (0 ºC) and that at this stage, the 
interaction between PEX5 and the DTM was still reversible (196). After docking, 
PEX5 becomes inserted into the DTM and the cargo protein is released into the 
peroxisomal matrix (196–198). Contrary to the docking step, translocation of PEX5 
(and cargo protein) only occurs at higher temperatures (>16 ºC) and the 
interaction between PEX5 and the DTM becomes essentially irreversible ((196, 
199), see below).  PEX5 at this stage displays a transmembrane topology having 
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most of its polypeptide chain facing the peroxisomal matrix, whereas a 2-kDa N-
terminal portion remains exposed to the cytosol (200, 201). Importantly, this 
insertion of PEX5 into the DTM is a cargo protein-dependent process (202). These 
observations are at the basis of the current model proposing that PEX5 pushes 
cargo proteins across the peroxisomal membrane as it gets inserted into the DTM 
(156, 197, 203). Remarkably, in vitro import experiments have shown that neither 
insertion of PEX5 into the DTM nor translocation of cargo proteins across the 
peroxisomal membrane are affected by non-hydrolyzable ATP analogs or by ATP 
depletion of the import assays (196, 198, 203). Likewise, ionophores have no 
effect on any of these events (198), in agreement with the fact that the 
peroxisomal membrane is readily permeable to small ions/molecules (204, 205). 
Apparently, the PIM uses neither the energy of ATP hydrolysis nor a membrane 
potential to transport proteins from the cytosol into the organelle matrix. 
Altogether, these findings led to the proposal that the driving force for the cargo 
protein translocation step resides in the strong protein-protein interactions that 
PEX5 establishes with components of the DTM (203). 
 
PEX5 monoubiquitination 
The first clue that ubiquitin should play some role in the peroxisomal protein 
import pathway dates back to 1992 when one of the yeast genes involved in this 
pathway was found to encode the ubiquitin-conjugating enzyme, PEX4 (206). The 
awareness, a few years later, that the three RING peroxins present in all 
peroxisome-containing organisms might well be members of a vast family of 
ubiquitin ligases E3s (207), fed this suspicion. However, the main mechanistic 
connection between ubiquitin and the PIM remained elusive for many years. As 
stated above, DTM-embedded PEX5 exposes approximately 2 kDa of its N 
terminus to the cytosol. This small N-terminal domain includes a cysteine-
containing motif that is conserved not only in PEX5 proteins from all organisms, 
but also in the PTS2 co-receptors PEX20, PEX18 and PEX21. Interestingly, 
deletion of this domain or the substitution of the cysteine residue on these 
peroxins did not affect their capacity to get inserted into the DTM, but rendered 
them completely incompetent in the export step (199, 208–210). The significance 
of these observations finally became clear when PEX5 was found to be 
monoubiquitinated at this cysteine residue (211, 212). More recent data also 
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confirmed that the PTS2 co-receptors, PEX20 and PEX18, are also ubiquitinated 
at the conserved cysteine residue (213, 214). 
 Monoubiquitination of PEX5 is absolutely mandatory for the next step of this 
import pathway, the extraction of monoubiquitinated PEX5 back into the cytosol 
(211, 215). In agreement, yeast strains lacking PEX4 do not monoubiquitinate 
PEX5 (212), and are unable to recycle peroxisomal PEX5 back into the cytosol 
(215). Orthologs of both PEX4 (and PEX22, its membrane anchor) have been 
found using bioinformatic analyses in several yeasts/fungi and plants, suggesting 
that all these organisms have a peroxisomal E2 dedicated to the peroxisomal 
protein import pathway (60, 61, 216). Strikingly, however, no orthologs could be 
found in mammals and many other organisms. Proteomic studies aiming at 
identifying new mammalian peroxisomal proteins also failed to reveal the 
existence of a peroxisome-bound E2 (217–219). Remarkably, the E2 activity 
acting on mammalian PEX5 was found to be confined to the cytosol, and 
purification of this activity led to the identification of three almost identical cytosolic 
E2s, E2D1/2/3 (UbcH5a/b/c in humans) (147), a group of multipurpose E2s 
involved in many other biological pathways (220, 221). 
 As mentioned earlier, three of the five core components of the DTM are the 
RING peroxins, PEX2, PEX10 and PEX12 which strongly suggested that the DTM 
itself is the E3 ligase catalyzing PEX5 monoubiquitination. Interestingly, several 
studies suggest that PEX5 can still enter the DTM in cells lacking RING peroxins 
(140, 222, 223). Apparently, and similarly to multi-subunit E3s (224), the substrate-
recruiting function of the DTM/E3 resides not in the RING peroxins but rather in 
other subunits of the complex (e.g. PEX14 and PEX13.) In vitro ubiquitination 
assays using recombinant RING Zn2+-binding domains from yeast and plant RING 
peroxins have shown that they all display E3 activity when assayed with human 
UbcH5 (225, 226) or with yeast PEX4 (227). More recently, in vitro ubiquitination 
assays with the mammalians counterparts showed similar results for PEX10 and 
PEX2 (228). Interestingly, while PEX12 has no E3 activity per se, it stimulated the 
E3 activity of PEX10 (228). In principle, one RING peroxin alone could promote 
monoubiquitination of PEX5 at the conserved cysteine. However, recent in vivo 
data seem to suggest that the RING peroxins are not redundant and that all three 
together are required for receptor ubiquitination (214).  
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 It is unclear why PEX5 is ubiquitinated at a cysteine residue instead of the 
more classical lysine residue (229). Substitution of the conserved cysteine residue 
in PEX5 by a lysine results in a seemingly normal protein that enters the DTM, 
receives a single ubiquitin molecule and is exported back into the cytosol as 
efficiently as the wild-type protein in in vitro assays (230). Furthermore, when 
expressed in embryonic fibroblasts from a PEX5 knockout mouse, this PEX5 
mutant protein is capable of reinstating peroxisomal protein import, as efficiently 
as the wild-type PEX5 protein (230). Nevertheless, some hypotheses regarding 
the conserved cysteine have been formulated. These include the possibility to 
deubiquitinate cytosolic Ub-PEX5 using a non-enzymatic mechanism (see below 
section “PEX5 deubiquitination”) or the potential to block the DTM under some 
conditions (e.g., oxidative stress) through chemical modification of the conserved 
cysteine residue (e.g., oxidation, glutathiolation, nitrosylation). In fact, a recent 
study demonstrated that protein import to the peroxisomal matrix is a redox-
sensitive process, a property that was Cys 11-dependent. Additionally, this study 
also showed that PEX5, when exposed to oxidized glutathione, becomes unable to 
undergo monoubiquitination. Therefore, it was proposed that the conserved 
cysteine residue may function as a redox switch that regulates PEX5 activity in 
response to oxidative stress (231). Theoretically, obstruction of the DTM by 
export-incompetent PEX5 molecules would result in a cytosolic localization for 
newly synthesized peroxisomal enzymes (e.g., catalase, epoxide hydrolase and 
glutathione S-transferase κ), a situation that might be advantageous under some 
stress conditions (see also (11, 230)). 
 
 PEX5 dislocation to the cytosol 
As stated above, the interaction of DTM-embedded PEX5 (i.e. stage 2 
PEX5) with components of this membrane module is essentially irreversible (199). 
Therefore, it is not surprising that extraction of the receptor back into the cytosol 
requires energy input. Indeed, it has been shown that extraction of Ub-PEX5 from 
the DTM requires ATP hydrolysis. It is presently believed that monoubiquitination 
of DTM-embedded PEX5 serves no purpose other than preparing the receptor for 
the export step, as it is necessary neither for the docking/insertion steps of PEX5 
into the DTM nor for cargo protein translocation and release into the peroxisomal 
matrix. (196, 198). PEX5 mutant proteins that cannot be monoubiquitinated are not 
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substrates for the REM and accumulate at the DTM. Likewise, monoubiquitination 
of PEX5 in in vitro import assays using a GST-ubiquitin fusion protein leads to the 
same outcome (211). Altogether, these findings suggest that it is not the covalent 
modification of PEX5 per se that prepares the receptor for the export step (e.g., by 
inducing a conformational alteration of PEX5), but rather that the ubiquitin moiety 
in the DTM-embedded Ub-PEX5 conjugate provides a context-specific “handle” for 
the REM. 
How the REM peroxins, PEX1 and PEX6, recognize DTM-embedded Ub-
PEX5 remains largely unknown. Nevertheless, recent data suggest that the 
interaction between Ub-PEX5 and the REM may not be direct (232). Indeed, using 
a mammalian in vitro import/export assay, Fujiki and co-workers found a cytosolic 
protein that stimulated export of PEX5 from the DTM. The protein was identified as 
AWP1, an ubiquitin-binding protein best known for its participation in the NF-κB 
signaling pathway (233). Further biochemical characterization of this protein led 
the authors to propose that AWP1 mediates the interaction between 
monoubiquitinated PEX5 and the REM (232). 
 
 PEX5 deubiquitination 
 Export of monoubiquitinated PEX5 from the DTM can be easily observed 
using a mammalian peroxisomal in vitro assay, particularly if the export reaction is 
made in the presence of a general deubiquitinase (DUB) inhibitor (e.g., ubiquitin 
aldehyde) (230). In contrast, all attempts to detect the mammalian or yeast Ub-
PEX5 thioester conjugate in cytosolic fractions obtained from cells/organs yielded 
negative results; Ub-PEX5 could only be detected in organelle fractions (212, 
230). Apparently, in vivo Ub-PEX5 is deubiquitinated very rapidly after export from 
the DTM. Recently, UBP15 in Saccharomyces cerevisiae and USP9X in mammals 
have been identified as the deubiquitinating enzymes (DUBs) acting on Ub-PEX5. 
Interestingly, however, knockout and knockdown of UBP15 and USP9X genes, 
respectively, did not result in the cytosolic accumulation of Ub-PEX5 (234, 235) 
suggesting there are other ways to deubiquitinate PEX5. These may include other 
less specific/active DUBs (234, 235) or, as proposed previously, even a non-
enzymatic mechanism because the thioester bond linking ubiquitin to PEX5 is 
much more labile than the typical isopeptide bond found in most ubiquitin 
conjugates. Indeed, soluble Ub-PEX5 (but not DTM-embedded Ub-PEX5) is easily 
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disrupted in the presence of 5 mM glutathione (a physiological concentration) 
displaying a half-life of just 2.3 min (230). Ultimately, deubiquitination of PEX5 
frees the receptor to undergo a new round of peroxisomal matrix protein import.   
 
 
3.2.2. Polyubiquitination of PEX5 
 
 Monoubiquitination of PEX5 is not the only type of ubiquitination occurring 
at the DTM. In yeast mutant strains lacking PIM components that act at late steps 
of the pathway (i.e., PEX5 monoubiquitination and its ATP-dependent dislocation 
from the DTM), small amounts of polyubiquitinated PEX5 are detected in 
peroxisomes (236–238). Furthermore, the steady-state levels of PEX5 are 
diminished in some of these mutant strains (223) suggesting that this 
polyubiquitination event targets PEX5 for proteasomal degradation (see Figure 2). 
A similar decrease in the steady-state levels of PEX5 in human cell lines from 
some patients with Peroxisome Biogenesis Disorders was also reported (169, 
239). Further characterization of this phenomenon in yeasts revealed that 
polyubiquitination of PEX5 is mediated not by the peroxisome-dedicated E2 PEX4, 
but by the multipurpose E2s Ubc1/Ubc4/Ubc5 (236–238). Polyubiquitination of 
PEX5 does not seem to occur at the conserved cysteine residue; rather, one or 
two lysines located near the conserved cysteine have been identified as the 
ubiquitination sites (212, 240). Although polyubiquitination of PEX5 has not yet 
been detected in wild-type strains, and substitution of those two PEX5 lysines by 
arginines has no phenotypic effects (215), it is possible, nevertheless, that this 
alternative way to remove PEX5 from the DTM is important whenever the normal 
recycling mechanism cannot be used. Polyubiquitination events have also been 
reported for PEX18 and PEX20, targeting these proteins for proteasome 
degradation (213, 214, 241). Interestingly, a recent study suggested that 
dysfunctional mammalian PEX7 might undergo a similar quality control 
mechanism in a process mediated by the Cullin4A-RING ubiquitin E3 ligase (242). 
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AIMS 
Our current knowledge on the pathway followed by the receptor PEX5 
during the PTS1 protein import process is reasonably detailed (16, 156, 243, 244). 
In contrast, our knowledge on the pathway followed by PEX7 during the PTS2 
protein import is still incomplete. Actually, for mammalian PEX7, besides a recent 
report showing that the protein associates with peroxisomes and acquires a 
protease-protected status in a cytosolic ATP-independent manner not much else is 
presently known (245). Interestingly, that study also proposed that, contrary to 
PEX7, the translocation of the PTS2 protein itself would require ATP, a conclusion 
that is probably incorrect, as discussed in detail in a previous work from our 
laboratory (198). Indeed, we found that the translocation of a PTS2 protein across 
the peroxisomal membrane occurs upstream of PEX5 monoubiquitination, i.e. 
independently of cytosolic ATP, a finding that was later extended to PTS1 proteins 
(196).  
Data on PEX7 from yeasts are somewhat more abundant, but not 
necessarily more clear. For instance, it has been suggested that yeast PEX7 
interacts first with the PTS2 cargo protein and subsequently with a member of the 
PEX20 family (PEX20, PEX18 or PEX21); this cytosolic trimeric complex then 
interacts with the DTM, leading to the translocation of the cargo protein into the 
matrix of the organelle (246). Such pathway would suggest that PEX7 reaches the 
peroxisome in a cargo-dependent manner, as is in fact the case for mammalian 
PEX5 working in the PTS1 protein import pathway (202). Intriguingly, however, 
PEX7 can also be found in peroxisomes in strains lacking PEX20 and that, 
therefore, do not import PTS2 proteins (208).  
There are also some data on the intraperoxisomal pathway followed by 
yeast PEX7. According to Lazarow and co-workers this protein is completely 
translocated across the peroxisomal membrane during its normal protein transport 
cycle (186). However, as stated above, these organisms use a member of the 
PEX20 family, and not PEX5, to transport PEX7-PTS2 cargo protein complexes to 
the peroxisome. Additionally, contrary to what was described for mammalian 
PEX7, translocation of the yeast peroxin across the peroxisomal membrane was 
recently proposed to occur downstream of the ubiquitination of PEX18 and 
therefore dependent on ATP hydrolysis (213).   
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Clearly, these conflicting data call for additional work. Therefore, in an 
effort to characterize the properties of PEX7 and PEX5 working on the PTS2 
import pathway, we have optimized a previously described in vitro import system 
that was used to characterize the translocation step of thiolase. One of the first 
questions we wanted to address was how mammalian PEX7 is targeted to 
peroxisomes. Is this process PTS2-protein dependent? Does PEX7 translocate 
the peroxisomal membrane completely or is it retained at the DTM, similarly to 
PEX5 functioning in the PTS1 import pathway? What are the energetic 
requirements of the PEX7-mediated import pathway? Additionally, we also wanted 
to characterize the PEX7 recycling step. Does PEX7 undergo any posttranslational 
modification (e.g., ubiquitination)? Is its export ATP-dependent? Could the 
processing of PTS2 proteins be the triggering step for cargo release or required for 
the export of PEX7? Finally, is PEX7 exported together with the receptor PEX5?  
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Plasmids 
 
pGEM4-PEX7- The cDNA coding for the full-length human PEX7 was obtained by 
PCR amplification using the plasmid SC119985 (OriGene) as template and the 
primers 5’.GCCTCTAGAGCCACCATGAGTGCGGTGTGCGGTGGA.3’ and     
5’.GCGCGGTACCTCAAGCAGGAATAGTAAGAC.3’. The amplified fragment was 
cloned into the XbaI and the KpnI sites of pGEM4® (Promega). 
pGEM4-PEX7(L70W)- A plasmid encoding PEX7 possessing a tryptophan instead 
of a leucine at position 70 (PEX7(L70W)) was obtained with the QuikChange® site-
directed mutagenesis kit (Stratagene) using pGEM4-PEX7 as template and the 
primers 5’.GGAATGATGGTTGGTTTGATGTGACTTGG.3’ and 5’.CCAAGTCACAT 
CAAACCAACCATCATTCC.3’. 
pGEM4-preL4RPEX7- A plasmid encoding a PEX7 protein possessing at its N 
terminus the peptide MAQRRQVVLGHLRGPADSGWMPQAAPCLSGASR 
(preL4R-PEX7) was constructed as follows. The plasmid SC119985 was used as 
template in a PCR reaction with the primers 5’.GCCTCTAGAATGAGTGCG 
GTGTGCGGTGGA.3’ and 5’.GCGCGGTACCTCAAGCAGGAATAGTAAGAC.3’. The 
obtained DNA fragment was inserted into XbaI/KpnI-digested pGEM4® (Promega). 
This plasmid was then digested with SphI and XbaI and ligated to the pre-
annealed primers 5’.CCACCATGGCGCAGAGGCGGCAGGTAGTGCTGGGCCACCTGAG 
GGGTCCGGCCGATTCCGGCTGGATGCCGCAGGCCGCGCCTTGCCTGAGCGGTGCCT.3’ 
and 5’.CTAGAGGCACCGCTCAGGCAAGGCGCGGCCTGCGGCATCCAGCCGGAATCG 
GCCGGACCCCTCAGGTGGCCCAGCACTACCTGCCGCCTCTGCGCCATGGTGGCATG.3’. 
The peptide preceding PEX7 in the pre-L4R-PEX7 fusion protein contains amino 
acid residues 2-30 of human pre-thiolase in which leucine 4 was replaced by an 
arginine (numbering of full-length human pre-thiolase (247)). This peptide still 
contains the cleavage site for the matrix processing peptidase, but the L4R 
mutation abolishes its PTS2 function (248). 
pGEM4-pre-Thiolase- The plasmid encoding full-length human thiolase precursor 
was described elsewhere (198). 
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pGEM4-preL4R-Thiolase- A plasmid coding for pre-thiolase possessing the L4R 
mutation was obtained with the QuickChange® site-directed Mutagenesis Kit 
(Stratagene), using pGEM4-pre-Thiolase as template and the primers 
5’.ATGCAGAGGCGGCAGGTAGTGCTGGG.3’and 5’.CCCAGCACTACCTGCCGCCT 
CTGCAT.3’. 
pGEM4-PEX5L- The plasmid encoding the large isoform of human PEX5 (PEX5L) 
was described before (200). 
pET28-∆C1PEX5L(C11A)- The plasmid encoding amino acid residues 1-324 of 
PEX5L possessing an alanine at position 11 (∆C1PEX5L(C11A)) was obtained 
with the QuikChange® site-directed mutagenesis kit (Stratagene), using pET28-
∆C1PEX5L as template (147) and primers described elsewhere (230). 
pET28-PEX7- The cDNA coding for histidine-tagged PEX7 (His6PEX7) was 
obtained by PCR amplification using the plasmid SC119985 (OriGene) as 
template and the primers 5’.GTATGAGCCATATGAGTGCGGTGTGCGGTGGAG.3’ 
and 5’.GGCCGCGGAATTCTCAAGCAGGAATAGTAAGAC.3’. The amplified fragment 
was cloned into the NdeI and the EcoRI sites of pET-28a (Novagen). 
pQE31-PHYH- The plasmid encoding the precursor form of human Phytanoyl-CoA 
hydroxylase (p-PHYH) was described in (249).  
pQE31-m-PHYH- The cDNA encoding the mature form of this protein (m-PHYH) 
was obtained by PCR amplification of the plasmid pQE31-PHYH using the primers 
5’.GGCGCGGTACCATCAGGGACTATTTCCTCTGCC.3’ and 5’.GGCGCAAGCTTTCA 
AAGATTGGTTCTTTCTCC.3’ and cloned into the KpnI and HindIII sites of pQE31 
(Qiagen).  
pGEM4-PHYH- The plasmid encoding the precursor form of human Phytanoyl-
CoA hydroxylase was obtained by PCR amplification of the plasmid pQE31-PHYH 
using the primers 5’.GACAAAGCTTGCCACCATGGAGCAGCTTCG.3’ and 
5’.GGGCGCGAATTCTCAAAGATTGGTTCTTTCTC.3’ and cloned into the HindIII 
and EcoRI sites of pGEM4® (Promega). 
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pQE31-PHYH(∆29-30) and pGEM4-PHYH(∆29-30)- Plasmids encoding a mutant 
version of p-PHYH where the residues Pro29 and Thr30 were deleted. These were 
obtained with the QuikChange® site-directed mutagenesis kit (Stratagene), the 
primers 5’.GGGGCTGTCGTAGCTCATTCAGGGACTATTTCCTCTGC.3’ and 
5’.GCAGAGGAAATAGTCCCTGAATGAGCTACGACAGCCCC.3’ and the plasmids 
pQE31-PHYH and pGEM4-PHYH as the respective templates.      
   
Recombinant Proteins 
 
 The recombinant large isoform of human PEX5 (PEX5L) (168), PEX5L 
containing the missense mutation N526K (PEX5L(N526K)) (209), proteins 
comprising amino acid residues 1-324 or 315-639 of PEX5L (∆C1PEX5L and 
TPRs, respectively) and ∆C1PEX5L containing the missense mutation C11A 
(∆C1PEX5L(C11A)) (147, 171), a protein comprising the first 287 amino acid 
residues of the small isoform of human PEX5 (∆C1PEX5S) (198), the GST-
ubiquitin fusion protein (GST-Ub) (211), the precursor of human Phytanoyl-CoA 
hydroxylase (p-PHYH), its mature form (m-PHYH) and the mutant PHYH(∆29-30) 
(249), human PEX19 (128) and a protein comprising the first 80 amino acid 
residues of human PEX14 (NDPEX14) (171), were obtained as described 
previously. Histidine-tagged PEX7 was expressed in the BL21(DE3) strain 
of Escherichia coli and obtained as inclusion bodies. The fusion protein was 
purified by HIS-SelectTM nickel affinity gel (Sigma) under denaturing conditions (6 
M Guanidine Hydrochloride) and concentrated by trichloroacetic acid precipitation. 
 
 
Preparation of postnuclear supernatants (PNS) from rat and mouse liver 
 
 Rat liver PNS fractions for in vitro assays were prepared from male Wistar 
rats with 6 to 8 weeks of age. The animal was fasted overnight, made unconscious 
in a CO2 chamber and euthanized by cervical dislocation. The liver was quickly 
homogenized in ice-cold SEM buffer (0.25 M sucrose, 20 mM MOPS-KOH, pH 
7.2, 1 mM EDTA-NaOH, pH 8.0) supplemented with 2 µg/ml N-(trans-
epoxysuccinyl)-L-leucine 4-guanidinobutylamide (E-64). After centrifuging the 
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homogenates twice at 600 x g for 10 min at 4 ºC (SS-34 rotor in a RC5B Sorvall® 
centrifuge), the resulting supernatant was aliquoted, frozen in liquid nitrogen and 
stored at -70 ºC. Postnuclear supernatants from PEX7 knockout male mice with 
approximately 12 weeks of age were prepared exactly as described above. Protein 
content of PNS fractions was determined using the Bradford method of protein 
quantitation. 
 
 
In Vitro Import/Export Reactions 
 
In a typical import reaction (100 µl final volume), 35S-labeled proteins (1-2 µl 
of the rabbit reticulocyte lysates; see below) were diluted to 10 µl with import buffer 
(20 mM MOPS-KOH, pH 7.4, 0.25 M sucrose, 50 mM KCl, 3 mM MgCl2, 20 µM 
methionine, 2 µg/ml E-64, 2 mM reduced glutathione, final concentrations) and 
added to 500 µg of liver PNS that had been primed for import (5 min incubation at 
37 ºC in import buffer containing 0.3 mM ATP; see (198, 203) for details). 
Reactions were incubated for 30 min at 37 °C, unless otherwise stated. ATP or 
AMP-PNP were used at 3 mM, final concentration. NTP depletion from both PNS 
and reticulocyte lysates using apyrase (Grade VII, Sigma) was done exactly as 
described (196). Where indicated, import reactions were supplemented with 
recombinant PEX5 proteins (PEX5L, PEX5L(N526K), ∆C1PEX5L, 
∆C1PEX5L(C11A) or ∆C1PEX5S; 30 nM final concentrations), GST-Ub or bovine 
ubiquitin (10 µM), and recombinant p-PHYH, m-PHYH or p-PHYH(∆29-30) (140 
nM, final concentration). After import, reactions were treated with pronase (500 
µg/ml final concentration) for 45 min on ice and processed for SDS-
PAGE/autoradiography exactly as described before (198). In some experiments, 
organelles were resuspended in import buffer and subjected to pronase digestion 
in the presence or absence of 1% (w/v) Triton X-100. 
In the in vitro export assays, radiolabeled proteins were first subjected to an 
import assay for 15 min. Further import was then stopped either by adding 
recombinant NDPEX14 to the reaction (30 µM final concentration), or by isolating 
the organelles by centrifugation and resuspending them in import buffer. In earlier 
experiments, cytosolic proteins derived from 500 µg of liver PNS were also added. 
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The organelle suspensions were then incubated at 37 ºC in the presence of either 
5 mM ATP or AMP-PNP. 
For the PTS2-only in vitro import/export experiments, PNS were pre-
incubated with 1 µM recombinant TPRs for 10 min on ice, before starting the 
import assays. This recombinant protein, corresponding to the C-terminal half of 
PEX5, comprises its PTS1-binding domain and is used here to sequester 
endogenous PTS1-containing proteins (174, 202, 209). Also, the reticulocyte 
lysates containing 35S-PEX7 and 35S-PEX5L (2 µl each) were pre-incubated with 
recombinant p-PHYH (20 min at 23 ºC in 10 µl of import buffer) to favor formation 
of the trimeric PEX5L-PEX7-PTS2 complex. The export incubation was carried out 
as described above, but in the presence of 1 µM TPRs and 10 µM NDPEX14. 
Any variations in protocol (duration of the import assays, concentrations of 
recombinants, incubation conditions) are explicitly referred to in the corresponding 
figure legend or when describing the experiment in the results section.    
 
 
Fractionation of organelles by sonication and centrifugation 
 
Pronase-treated organelles from an import reaction or rat liver purified 
peroxisomes were resuspended in 20 mM MOPS-KOH, pH 7.4, 0.25 M sucrose, 1 
mM EDTA, 2 mM DTT, 0.1 mg/ml phenylmethanesulfonylfluoride, 1:500 (v/v) 
mammalian protease inhibitors mixture (Sigma) and disrupted by sonication using 
a SONOPULS HD2200-BANDELIN equipped with a MS 73 microtip. The 
sonication conditions used (40% duty cycle, 10% output power for just 25 s) were 
established as the mildest ones resulting in a quantitative extraction of catalase 
from peroxisomes. Membrane and matrix components were separated by 
centrifugation at 100,000 g for 60 min at 4 ºC. 
 
 
Miscellaneous 
 
All 35S-labeled proteins were synthesized using the TNT® T7 quick coupled 
transcription/translation kit (Promega) in the presence of [35S]methionine (specific 
activity >1000 Ci/mmol; PerkinElmer Life Sciences). The antibody directed against 
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human PEX7 was produced in rabbits using recombinant histidine-tagged PEX7. 
The antibody directed to PEX13 was described elsewhere  (122) and the one 
against catalase was purchased from Research Diagnostics, Inc. (catalogue 
number RDI-CATALASEabr). All antibodies were detected using goat alkaline 
phosphatase-conjugated anti-rabbit antibodies (A9919; Sigma). 
Densitometric analyses of autoradiography films were performed using the 
ImageJ software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997–2011). 
The number or DTMs per peroxisomes was estimated as follows: 1 g of rat 
liver has the equivalent of 260 mg of total protein and an estimated 5.9 x1010 
peroxisomes (67, 250). Approximately 2.5% of the total proteins corresponds to 
peroxisomal protein (67) (2.5% x 260 mg = 6.5 mg of peroxisomal protein/ g of 
liver). PEX14 was estimated at 0.25% of all peroxisomal protein (142) (0.25% x 
6.5 mg = 16.25 µg of PEX14/ g of liver). With a MW of ~41 kDa, 16.26 µg of 
PEX14 corresponds to 4.0 x10-10 moles or 2.4 x1014 molecules of PEX14/ g of 
liver. Dividing by the number of peroxisomes, we obtain a number of 4,000 
molecules of PEX14 molecules per peroxisome. Considering a theoretical ratio of 
7 molecules of PEX14 per DTM (a molar ratio of 1:7 was determined for PEX5 and 
PEX14 at the peroxisomal membrane (142)), we estimate that there are 
approximately 500 DTMs per peroxisome.   
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1. PEX7 reaches the peroxisome in a PEX5L- and PTS2-dependent manner.  
 
Protein in vitro import systems have been used with great success to 
understand how peroxisomal matrix proteins are imported into peroxisomes. 
Essentially, an in vitro import reaction consists in incubating a 35S-labeled reporter 
protein with an organelle suspension under physiological conditions. After 
incubation, large amounts of a non-specific protease are added to the reaction to 
degrade non-imported 35S-labeled protein while the fraction that was imported into 
the organelles is preserved. We have recently described an improved in vitro 
system to characterize the peroxisomal import mechanism of pre-thiolase, a 
PTS2-containing protein (198). The system relies on a rat liver postnuclear 
supernatant as a source of peroxisomes and cytosolic components, supplemented 
with either recombinant ∆C1PEX5L (amino acid residues 1-324 of PEX5L) or 
PEX5L(N526K) (PEX5L possessing a lysine at position 526 instead of an 
asparagine). These two PEX5 proteins contain an intact PEX7-binding domain as 
well as all the other elements required for a productive interaction with the 
peroxisomal protein import machinery (145, 209), and thus they are still competent 
in the PTS2-mediated import pathway. However, they do not bind efficiently PTS1 
proteins (145, 148, 199, 251), an advantage when studying the PTS2-mediated 
import pathway (see below). In this work we used this improved system to 
characterize the pathway followed by PEX7 during the protein transport cycle it 
promotes. 
 
Figure 4 shows the results of in vitro import assays performed with both 35S-
labeled PEX7 and 35S-pre-thiolase. In the absence of ∆C1PEX5L, or in the 
presence of ∆C1PEX5S (a protein almost identical to ∆C1PEX5L that lacks the 
PEX7-binding domain; see Introduction), only a small fraction of protease-
protected (imported) thiolase was observed in organelle pellets, as expected 
(198), and the same is true for 35S-PEX7 (lanes 1 and 3). A 5-fold increase in the 
amounts of both radiolabeled proteins was observed when the import assays were 
supplemented with either recombinant ∆C1PEX5L or PEX5L(N526K) (lanes 2 and 
5). Recombinant PEX5L also improves the import efficiencies of both pre-thiolase 
and PEX7 but only by a factor of ≈ 2.5 (compare lanes 1 and 4). The weaker 
stimulatory effect obtained with PEX5L is probably due to the fact that this protein 
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also interacts with endogenous PTS1-containing proteins present in the PNS, 
creating a competition problem at the peroxisomal DTM (see also (198)). 
 
 
 
Figure 4. 
35
S-labeled PEX7 acquires a protease-protected status in in vitro import 
reactions fortified with PEX5L(N526K) or ∆C1PEX5L. 
 A rat liver PNS was incubated with 35S-labeled PEX7 and 35S-pre-thiolase in import buffer 
containing ATP in the absence (lane 1) or presence of recombinant ∆C1PEX5L (lane 2), 
∆C1PEX5S (lane 3), PEX5L (lane 4), or PEX5L(N526K) (lane 5). Pronase-treated organelles 
were analyzed by SDS-PAGE and blotted onto a nitrocellulose membrane. Lane I, 10% of 
the reticulocyte lysates containing 35S-PEX7 and 35S-pre-thiolase used in each reaction.  
Autoradiographs (upper panels) and corresponding Ponceau S-stained membrane (lower 
panel) are shown. Numbers to the left indicate the molecular masses of the protein 
standards in kDa. The asterisk marks a radiolabeled band occasionally produced by the in 
vitro translation kit in an unspecific manner. pre-Thiol and m-Thiol refer to the precursor and 
mature forms of thiolase, respectively. 
 
The in vitro import yields of 35S-PEX7 obtained in the presence of 
∆C1PEX5L can be further improved by a factor of 2 when a recombinant PTS2 
protein, pre-phytanoyl-CoA 2-hydroxylase (p-PHYH), is added to the assay (Figure 
5A, compare lanes 3 and 4). The stimulatory effect of p-PHYH on PEX7 import 
contrasts with its inhibitory effect on pre-thiolase import (Figure 5A, compare lanes 
3 and 4). Recombinant phytanoyl-CoA 2-hydroxylase lacking the PTS2 (m-PHYH) 
has no such effects (Figure 5B, compare lane 1 with 2 and 3, respectively). These 
findings strongly suggest that the 35S-PEX7 protein used in these experiments is 
truly functioning in the PTS2-mediated protein import pathway.  
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Figure 5. Import of 
35
S-PEX7 is stimulated in the presence of a recombinant PTS2-
containing protein. 
A, A rat liver PNS was incubated with 35S-labeled PEX7 and 35S-pre-thiolase in import buffer 
containing ATP in the absence (lanes 1 and 2) or presence of recombinant ∆C1PEX5L 
(lanes 3 and 4). Import reactions were supplemented (lanes 2, 4) or not (lanes 1, 3) with 
recombinant p-PHYH. Pronase-treated organelles were analyzed by SDS-PAGE and blotted 
onto a nitrocellulose membrane. B, ∆C1PEX5L-supplemented in vitro import assays of 35S-
PEX7 and 35S-pre-thiolase in the absence (lane 1) and in the presence of either p-PHYH or 
m-PHYH (lanes 2 and 3, respectively). Samples were processed as in A. Lanes I in A and B, 
10% and 5% of the reticulocyte lysates containing 35S-PEX7 and 35S-pre-thiolase used in 
each reaction, respectively. Autoradiographs (upper panels) and corresponding Ponceau S-
stained membranes (lower panels) are shown. Numbers to the left indicate the molecular 
masses of the protein standards in kDa. The asterisk in A marks a radiolabeled band 
occasionally produced by the in vitro translation kit in an unspecific manner. 
 
 
Further data corroborating this conclusion were obtained when a PNS from 
PEX7 knockout mice (252) was used in import assays. As shown in Figure 6, an 
assay using PNS from these mice supplemented with ∆C1PEX5L (and 2 µl of a 
mock-translated reticulocyte lysate) failed to reveal import of pre-thiolase (lane 1). 
In contrast, addition of just 2 µl of the lysate containing 35S-PEX7 was sufficient to 
promote import and partial processing of pre-thiolase (Figure 6, lane 2). A non-
functional PEX7 protein harboring a mutation previously described in a patient with 
Rhizomelic Chondrodysplasia Punctata Type 1 (PEX7(L70W); (253)) was used as 
a negative control and, as expected, was not competent in this assay (Figure 6, 
lane 3).  
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Figure 6. PEX7 but not PEX7(L70W) promotes import of 
35
S-pre-thiolase into 
peroxisomes from PEX7 knockout mice.  
PNS from PEX7 knockout mouse liver was used in import assays with 35S-pre-thiolase in the 
presence of either a mock-translated reticulocyte lysate (lane 1) or lysates containing 35S-
PEX7 (lane 2) or 35S-PEX7(L70W) (lane 3). Samples were processed as in Figure 4. Lanes 
I1, I2 and I3, 5% of the reticulocyte lysates containing 
35S-pre-thiolase, 35S-PEX7 and 35S-
PEX7(L70W) used in the reactions, respectively. Autoradiograph (upper panel) and 
corresponding Ponceau S-stained membrane (lower panel) are shown. Numbers to the left 
indicate the molecular masses of the protein standards in kDa. 
 
 
 
Figure 7. Imported 35S-PEX7 is protected from proteases by a lipid membrane. 
Organelles from an import assay made in the presence of recombinant  ∆C1PEX5L and p-
PHYH were isolated by centrifugation, resuspended in import buffer and subjected to 
pronase digestion in the absence (lane 1) or presence (lane 2) of 1% (w/v) Triton X-100. 
Lane I, 5% of the reticulocyte lysate containing 35S-PEX7. Autoradiograph (upper panel) and 
corresponding Ponceau S-stained membrane (lower panel) are shown. Numbers to the left 
indicate the molecular masses of the protein standards in kDa. 
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It is important to note that the resistance of in vitro imported PEX7 to the 
protease does not reflect an intrinsic property of PEX7 because no radiolabeled 
protein is detected when the protease treatment is made in the presence of Triton 
X-100, a mild detergent that solubilizes biological membranes (Figure 7, lane 2). 
Taken together, the experiments described above strongly suggest that in vitro 
synthesized PEX7 reaches the peroxisome in a PEX5L- and PTS2-dependent 
manner where it acquires a protease-protected status. 
 
 
2. The energetic requirements of PEX7 import.  
 
It was previously shown that: 1) PEX5L becomes inserted into the DTM in a 
cytosolic ATP-independent process (199, 200, 203), and 2) translocation of pre-
thiolase across the DTM into the peroxisomal matrix occurs upstream of the first 
cytosolic ATP-dependent step, i.e. before monoubiquitination of PEX5 (198). Not 
surprisingly, we found that the energetic requirements of PEX7 import are 
identical, as was in fact also reported by others (245). As shown in Figure 8A, 
neither supplementation of import reactions with AMP-PNP (a non-hydrolyzable 
ATP analog; (235, 254)), nor pre-treatment of the 35S-PEX7 protein and PNS with 
apyrase (an enzyme that hydrolyzes ATP and other NTPs; (255)) blocked PEX7 
import (compare lane 1 with lanes 2 and 3, respectively).  
 Interestingly, although export of peroxisomal PEX7 is ATP-dependent (see 
section IV-4 below), the levels of peroxisomal PEX7 observed under the different 
energetic conditions are identical. This finding suggests that export of PEX7 from 
the peroxisome becomes a rate-limiting step in this optimized in vitro import 
system. 
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Figure 8. The energetics of PEX7 import. 
A, A primed rat liver PNS fraction (see Experimental Procedures) was incubated with 35S-
PEX7 for 7 min in import buffer containing ∆C1PEX5L and p-PHYH in the presence of either 
ATP (lane 1), or AMP-PNP (lane 2). An identical assay but using apyrase-treated PNS and 
35S-PEX7 was also performed (lane 3). Lanes I1 and I2, 5% of the reticulocyte lysates 
containing 35S-PEX7 used in lanes 1 and 2 (- apyrase), and lane 3 (+ apyrase), respectively. 
B, A non-monoubiquitinatable form of PEX5 (∆C1PEX5L(C11A)) is as efficient as wild-type 
PEX5 in targeting PEX7 and pre-thiolase to the peroxisome. Import assays with 35S-PEX7 
and 35S-pre-thiolase were made in import buffer containing ATP and GST-Ub, in the absence 
(lane 1) or presence of recombinant ∆C1PEX5L (lane 2) or ∆C1PEX5L(C11A) (lane 3). Note 
that ubiquitination of ∆C1PEX5L with GST-Ub results in a species that is no longer export-
competent (147, 211). Pronase-treated organelles were analyzed as described in Figure 4. 
Autoradiographs (upper panels) and the corresponding Ponceau S-stained membranes 
(lower panels) are shown. Lane I, 5% of the reticulocyte lysates containing 35S-PEX7 and 
35S-pre-thiolase were mixed and loaded together in the same lane. 
 
The data in Figure 8A showing that PEX7 import is not blocked in assays 
containing apyrase, a condition previously shown to block PEX5 
monoubiquitination (196, 198), also suggests that import of PEX7, like import of 
pre-thiolase, occurs upstream of PEX5L-monoubiquitination. Additional data 
supporting this conclusion are presented in Figure 8B. Identical amounts of 
protease-protected 35S-PEX7 and thiolase were obtained in import reactions 
supplemented with either ∆C1PEX5L or ∆C1PEX5L(C11A), a mutant protein that 
possesses an alanine at position 11. The substitution of cysteine 11 by an alanine 
results in a PEX5 protein that can still enter the DTM but that is no longer 
monoubiquitinated (230). 
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3. The N terminus of peroxisomal PEX7 is exposed into the organelle matrix.  
 
The fact that peroxisomal 35S-PEX7 is resistant to exogenously added 
proteases suggests that PEX7 exposes no major domains into the cytosol but 
provides no clues on how deep in peroxisomes it reaches. To address this issue 
we adapted a strategy previously used by others to show that a portion of the 
polypeptide chain of peroxisomal PEX5 reaches the peroxisomal matrix (248). 
Specifically, we synthesized a PEX7 protein having at its N terminus a cleavable, 
but otherwise non-functional, mutant version of thiolase pre-sequence and asked 
whether this PEX7 protein (hereafter referred to as preL4R-PEX7) could be 
cleaved in our in vitro import assays. A control experiment with a pre-thiolase 
carrying the same mutation (L4R) confirmed that this mutant pre-sequence is not 
functional in our in vitro assays (Figure 9A and (256)).  
As shown in Figure 9B, preL4R-PEX7 subjected to in vitro import assays 
not only acquired a protease-resistant status in a PEX5L- and PTS2-dependent 
manner, but was also converted into a 2-3 kDa shorter protein. Furthermore, 
preL4R-PEX7, like PEX7, was also able to restore import of pre-thiolase in PNS 
from the PEX7 knockout mice (Figure 9C). Processing of preL4R-PEX7 requires 
its passage through the peroxisome because nearly no processed PEX7 could be 
detected when the import assays were performed in the presence of a 
recombinant protein comprising the PEX5-binding domain of PEX14 ((257); Figure 
10, compare lanes 1 and 5 with lanes 3 and 7, respectively). As shown before, this 
recombinant protein completely blocks the PEX5-mediated protein import pathway 
(196). Interestingly, when the protease treatment was omitted, cleaved PEX7 was 
also detected in the supernatant of the import assays but only under import-
permissive conditions (Figure 10, compare lanes 2 and 4) suggesting that our in 
vitro system can also be used to study PEX7 export.  
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Figure 9. PEX7 becomes transiently exposed to the organelle matrix during the PTS2-
mediated protein import pathway. 
A, 35S-pre-thiolase containing an arginine instead of a leucine at position 4 (preL4R-Thiol; 
lane 2) is not imported in vitro. Lanes I1, I2 and I3, 5% of the reticulocyte lysates containing 
35S-PEX7, 35S-pre-thiolase and 35S-preL4R-thiolase, respectively. B, 35S-preL4R-PEX7 was 
subjected to import assays in the absence (lane 1) or presence of the indicated recombinant 
proteins (lanes 2-4). Pronase-treated organelles were analyzed by SDS-PAGE and blotted 
onto a nitrocellulose membrane. clv-PEX7, cleaved 35S-preL4R-PEX7. C, 35S-preL4R-PEX7 
promotes import of 35S-pre-thiolase into peroxisomes from PEX7 knockout mice. PNS from 
PEX7 knockout mice was used in import assays with 35S-pre-thiolase in the presence of 
either a mock-translated reticulocyte lysate (lane 1) or a lysate containing 35S-preL4R-PEX7 
(lane 2). Import and processing of 35S-pre-thiolase is best seen in import assays using 
unlabeled/cold preL4R-PEX7 (lane 3) due to the fact that mature thiolase co-migrates with 
uncleaved pre-L4R-PEX7 (lane 2, asterisk). Lanes I1 and I2, 5% of the reticulocyte lysates 
containing 35S-preL4R-PEX7 and 35S-pre-thiolase used. Autoradiographs (upper panels) and 
corresponding Ponceau S-stained membranes (lower panels) are shown. Numbers to the left 
indicate the molecular masses of the protein standards in kDa. 
 
   IV- RESULTS 
51 
 
 
 
Figure 10. Processing of 
35
S-preL4R-PEX7 in import assays occurs only under import-
permissive conditions.  
35S-preL4R-PEX7 was subjected to import assays in the presence of the indicated 
recombinant proteins. At the end of the incubation the samples were halved and treated or 
not with pronase, as indicated. The import reactions were then centrifuged to obtain 
organelle pellets (P) and supernatants (S). Total pellets (derived from 500 µg of PNS) and ¼ 
of the corresponding supernatants were subjected to SDS-PAGE and blotted onto a 
nitrocellulose membrane. The asterisk indicates a soluble minor preL4R-PEX7-derived 
fragment displaying some resistance to pronase. PEX19, a protein involved in another 
aspect of peroxisome biogenesis (128), was used in these assays as a negative control for 
NDPEX14. . Lanes I, 5% of the reticulocyte lysates containing 35S-preL4R-PEX7 used in 
these assays. Autoradiograph (upper panel) and corresponding Ponceau S-stained 
membrane (lower panel) are shown. Numbers to the left indicate the molecular masses of 
the protein standards in kDa. 
  
 
Finally, and in agreement with the data shown in Figure 8B, cleavage of 
preL4R-PEX7 was also observed when its import was promoted by 
∆C1PEX5L(C11A) (Figure 11). Interestingly, when this export-incompetent PEX5 
species is used in these assays, almost no cleaved PEX7 is recovered in the 
supernatant fraction (Figure 11, compare lanes 3 and 4) suggesting that export of 
cleaved PEX7 is somehow dependent on PEX5 ubiquitination/export (see also 
below). In summary, these results indicate that at least the N terminus of PEX7 
reaches a location where it can be cleaved by the protease that processes PTS2 
proteins, i.e., the peroxisomal matrix. 
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Figure 11.  Accessibility of 
35
S-preL4R-PEX7 to the peroxisomal matrix does not 
depend on PEX5 ubiquitination/ export.  
Import assays with 35S-preL4R-PEX7 were performed in the presence of ∆C1PEX5L (lanes 
1 and 3) or ∆C1PEX5L(C11A) (lanes 2 and 4). Pronase-treated organelles (lanes P) and 
untreated supernatants (lanes S) were analyzed as in Figure 10. Lanes I, 5% of the 
reticulocyte lysate containing 35S-preL4R-PEX7 used in each reaction. Autoradiograph 
(upper panel) and corresponding Ponceau S-stained membrane (lower panel) are shown. 
Numbers to the left indicate the molecular masses of the protein standards in kDa. 
 
 
4. Export of PEX7 from the peroxisome requires export of PEX5L, but the 
two events are not strictly coupled.  
 
PEX7 functions as a shuttling receptor, meaning that peroxisomal PEX7 is 
eventually exported back to the cytosol (186). Aiming at characterizing in detail 
this process we developed a two-step protocol in which 35S-PEX7 is first subjected 
to an import assay, and after blocking further import (see Experimental Procedures 
for details), the organelle suspension is then subjected to a second incubation 
step, the export assay. The results of one of these assays performed under 
standard conditions show that the amount of organelle-associated protease-
protected 35S-PEX7 decreases over time with the concomitant appearance of 35S-
PEX7 in the supernatant (Figure 12). Note that there is a small amount of PEX7 
already in the soluble phase at 0 minutes of export. We attribute this to the release 
of a small amount of PEX7 that is unspecifically absorbed to the membrane when 
the protease-untreated organelles are resuspended. 
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Figure 12. In vitro imported PEX7 is exported back to the cytosol. 
35S-PEX7 was imported for 15 min in the presence of p-PHYH, ∆C1PEX5L, ubiquitin and 
ATP. The reaction mix was then diluted with ice-cold import buffer and the organelles were 
isolated by centrifugation and subjected to an export assay in the presence of ATP (see 
Experimental Procedures for details). Aliquots were collected at the indicated time points, 
and one half was treated with pronase while the other was left untreated. Equivalent 
amounts of organelles from the pronase-treated aliquots and supernatants from the 
untreated aliquots (derived from 125 µg of PNS) were analyzed by SDS-PAGE and blotted 
onto a nitrocellulose membrane. Lanes I, 5% of the reticulocyte lysates containing 35S-PEX7 
used in each reaction. Autoradiograph (upper panels) and the corresponding Ponceau S-
stained membrane (lower panels) are shown. Numbers to the left indicate the molecular 
masses of the protein standards in kDa. 
 
 
Interestingly, experimental conditions that inhibit export of peroxisomal 
PEX5 back into the cytosol, also block export of PEX7. As shown in Figure 13A, 
almost no export of PEX7 was detected in assays made in the presence of AMP-
PNP. This non-hydrolyzable ATP analogue still allows PEX5 monoubiquitination at 
the DTM but blocks the receptor export module (235). A similar inhibition was 
observed when both the import and export incubations were made in the presence 
of a GST-ubiquitin fusion protein (GST-Ub, Figure 13B). As shown before, 
ubiquitination of DTM-embedded PEX5 with this ubiquitin analogue results in a 
species that is no longer export-competent (211). Note that we have been unable 
to detect any ubiquitination of PEX7 in our in vitro assays (even under non-
reducing conditions; data not shown) suggesting that the effect of GST-Ub on 
PEX7 export occurs via PEX5. In agreement with this interpretation, and with the 
data shown in Figure 11, when 35S-PEX7 was imported in the presence of 
∆C1PEX5L(C11A) no significant export of 35S-PEX7 was detected (Figure 13C). 
Thus, peroxisomal PEX7 is exported back into the cytosol only when PEX5 is also 
exported. 
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Figure 13. PEX5 export is a requirement for PEX7 export. 
A-C, In “standard reactions”, the ∆C1PEX5L- and p-PHYH-mediated import of 35S-PEX7 was 
allowed to occur at 37 ºC for 15 min in the presence of ubiquitin and ATP. At this point, 
import was inhibited by the addition of NDPEX14 (30 µM) and the reaction further incubated. 
Aliquots were taken at the indicated time points. Pronase-treated organelles were subjected 
to SDS-PAGE analysis and blotted onto a nitrocellulose membrane. Autoradiograph (upper 
panels) and the corresponding Ponceau S-stained membrane (lower panels) are shown. 
Numbers to the left indicate the molecular masses of the protein standards in kDa. PEX7 
export was inhibited when ATP was replaced by AMP-PNP (A). Likewise, replacing ubiquitin 
by GST-Ub in the import step inhibits subsequent export of PEX7 (B). The same inhibition 
was observed when recombinant ∆C1PEX5L was replaced by ∆C1PEX5L(C11A) (C). Lanes 
I, 5% of the reticulocyte lysates containing 35S-PEX7 used in each assay. D, The bar graph 
shows the average percentage of PEX7 export after 20 min under the conditions described 
in A, B and C. Standard deviations (n≥3) are also presented. 
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 Several hypotheses could explain this phenomenon. An obvious one would 
be to assume that export of PEX7 is coupled to that of PEX5. Alternatively, it might 
be that PEX5 arrested at the DTM simply blocks the site used by PEX7 to exit the 
organelle. In an attempt to clarify this issue we determined the export kinetics of 
both proteins. Obviously, such an experiment would only be informative if we could 
find conditions where PEX5 would reach the peroxisome in a PTS2-only mode. 
With this in mind, we performed in vitro assays in the presence of a recombinant 
protein comprising the PTS1-binding domain of PEX5 (referred to as TPRs), a 
strategy previously shown to efficiently block the PTS1-dependent targeting of 
PEX5 to the peroxisome (202, 209), and asked whether peroxisomal targeting of 
35S-PEX5 could be recovered by adding 35S-PEX7 and recombinant p-PHYH to 
the import assays. As shown in Figure 14A, this strategy turned out to be feasible: 
import of 35S-PEX5L was now PEX7/PTS2-dependent. Using these experimental 
conditions we then employed the two-step import-export protocol described above 
to compare the export kinetics of 35S-PEX7 and 35S-PEX5L. Briefly, after an import 
step performed in presence of AMP-PNP, the organelles were isolated by 
centrifugation, resuspended in import buffer and subjected to an export assay. 
Aliquots were then withdrawn at various time points, and protease-treated 
organelles were analyzed by SDS-PAGE/autoradiography. As shown in Figure 
14B, two populations of 35S-PEX5L displaying different protease susceptibilities 
were detected in this experiment, as expected (199, 200, 211). The most abundant 
at time zero of the export step is the so-called stage 3 PEX5L, a DTM-embedded 
monoubiquitinated species that leaves the peroxisome very rapidly in the presence 
of ATP (Figure 14B, compare lanes 0’ and 2’; see also (199, 211) and legend to 
Figure 14B for additional details regarding the properties of peroxisomal PEX5L). 
The other population is stage 2 PEX5L (the precursor of stage 3 PEX5L), a non-
ubiquitinated species that is cleaved at its N terminus by the protease used in 
these assays yielding a 2-kDa shorter protein. Due to the fact that the buffer used 
in the export step lacked ubiquitin and components of the ubiquitin-conjugating 
cascade, the majority of stage 2 PEX5L was not converted into stage 3 PEX5L 
and therefore remained in the organelles. Densitometric analyses of 
autoradiographs revealed that about 70% of total peroxisomal 35S-PEX5L left the 
organelle in the first 2 min of the export incubation (Figure 14B, lower panel). 
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Importantly, the export kinetics of 35S-PEX7 is considerably slower, a difference 
particularly evident at the 2-min time point of the export assay. Apparently, when 
PEX5 is exported from the peroxisome it leaves behind a fraction of PEX7, a 
finding strongly suggesting that export of the two proteins is not coupled. In 
summary, the data in Figure 13 and 14 suggest that at least a fraction of PEX7 
and PEX5 leave the peroxisome separately but through the same site; the finding 
that no peroxisomal PEX7 is exported whenever PEX5 is arrested at the DTM 
suggests that DTM-embedded PEX5 behaves as a plug blocking the release of 
peroxisomal PEX7 into the cytosol (see also Discussion). 
 
 
Figure 14. Peroxisomal PEX5L and PEX7 display different export kinetics. 
A, Targeting of PEX5L to the peroxisome in a PTS2-only in vitro import system. A reticulocyte 
lysate containing 35S-PEX5L was pre-incubated with either a mock-translated lysate (lane 1) or 
a lysate containing 35S-PEX7 plus 0.5 µg of p-PHYH (lane 2). Each mixture was then subjected 
to import assays using PNS supplemented with ATP and 1 µM recombinant TPRs, the PTS1-
binding domain of PEX5. After pronase treatment, organelles were subjected to SDS-PAGE 
analysis and blotted onto a nitrocellulose membrane. Lanes I1 and I2, 5% of the reticulocyte 
lysates containing 35S-PEX7 and 35S-PEX5L used in the assays, respectively. B, Peroxisomal 
PEX5L and PEX7 are exported with different kinetics. A mixture of 35S-PEX7 and 35S-PEX5L 
pre-incubated with recombinant p-PHYH was subjected to a 15 min import assay using TPRs-
treated PNS in the presence of AMP-PNP. The reaction was diluted with ice-cold import buffer, 
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and the organelles were isolated by centrifugation, resuspended in import buffer and subjected 
to an export assay in the presence of ATP, TPRs and NDPEX14. Aliquots were collected at the 
indicated time points. Pronase-treated organelles were analyzed as in A. Lanes I1 and I2, 2% of 
the reticulocyte lysates containing 35S-PEX7 and 35S-PEX5L used in the assays, respectively. 
The bar graph shows averages and standard deviations (n=3) of the amounts of peroxisomal 
35S-PEX7, stage 2 35S-PEX5L (PEX5 stg2) and stage 3 35S-PEX5L (PEX5 stg3) at each time 
point. Stage 2 PEX5 is converted into stage 3 PEX5 by monoubiquitination at its cysteine 11. 
The two populations display different susceptibility to proteases: stage 2 PEX5 is cleaved near 
the N terminus yielding a 2-kDa shorter protein, whereas stage 3 PEX5 is completely resistant 
because the N-terminal domain is protected by the covalently attached ubiquitin moiety. Note 
that stage 3 PEX5L runs exactly as unmodified full-length PEX5L upon SDS-PAGE under 
reducing conditions because the PEX5-ubiquitin thiolester linkage is destroyed by DTT. The 
open arrow head in A and B indicates an export-incompetent N-terminally truncated PEX5L 
species produced in the in vitro transcription/translation reactions (see also (209)). This species 
also serves as an internal negative control in the export assay. 
 
 
5. Peroxisomal PEX5 engaged in the PTS2-import pathway remains tightly 
bound to the organelle membrane.  
 
 All the presently available data suggest that PEX5 shuttles between the 
cytosol and the peroxisomal DTM where it acquires a transmembrane topology, 
without ever entering completely into the organelle matrix (200, 202, 203, 211, 
258). However, it is important to note all those data were obtained with 
experimental systems in which PEX5 is mostly involved in the PTS1-mediated 
protein import pathway. Considering a previously proposed hypothesis that 
PEX20, the yeast functional counterpart of PEX5, may enter completely into the 
organelle matrix together with PEX7 (214), it might be possible that mammalian 
PEX5 functioning in the PTS2-import pathway also follows a similar route. To 
address this possibility we used the PTS2-dependent import assay described 
above and tried to determine whether 35S-PEX5L co-fractionates with either 
membrane or matrix peroxisomal proteins. Briefly, protease-treated organelles 
from import assays made in the presence of ATP or AMP-PNP were disrupted by 
sonication and subjected to ultracentrifugation to separate membrane from soluble 
proteins. The efficiency of this procedure was assessed by monitoring the 
behavior of catalase, a peroxisomal matrix protein (2, 259) and PEX13, an intrinsic 
peroxisomal membrane protein and a component of the DTM (260). As shown in 
Figure 15A, 35S-PEX5L quantitatively co-fractionated with the membrane marker 
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PEX13, thus strongly suggesting that peroxisomal PEX5 engaged in the PTS2-
protein import pathway remains tightly bound to the peroxisomal membrane. A 
different result was obtained for PEX7. Indeed, although a major fraction of 35S-
PEX7 was found in the membrane pellet some protein was also detected in the 
soluble fraction. A similar distribution was observed for endogenous rat liver PEX7 
present in highly pure peroxisome preparations (Figure 15B).  
  
 
 
Figure 15. Peroxisomal PEX5L engaging in PTS2 import remains tightly bound to the 
peroxisomal membrane, whereas a fraction of PEX7 behaves as a matrix protein. 
A, A mixture of 35S-PEX7 and 35S-PEX5L pre-incubated with p-PHYH was subjected to an 
import assay using TPR-treated PNS in the presence of ATP (left panel) or AMP-PNP (right 
panel), as indicated. After pronase treatment, organelles were disrupted by sonication. Half 
of the suspension was left on ice (lanes T) while the other half was subjected to 
ultracentrifugation to obtain membrane (P) and soluble (S) fractions. Samples were analyzed 
by SDS-PAGE and blotted onto a nitrocellulose membrane. Lanes I1 and I2, 2% of the 
reticulocyte lysates containing 35S-PEX7 and 35S-PEX5L used in the assays, respectively 
After autoradiography to detect 35S-PEX7 and 35S-PEX5L, the membrane was probed with 
antibodies against Catalase (α-CATALASE) and PEX13 (α-PEX13). PEX5 stg2 and PEX5 
stg3, stage 2 and stage 3 35S-PEX5L, respectively. Note that PEX13 is converted into 28- to 
30-kDa fragments after protease treatment (201) B, An identical sonication experiment was 
done using rat liver purified peroxisomes. The nitrocellulose membrane was also probed with 
antibodies against PEX7 (α-PEX7). 
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 The detection of a soluble population of PEX7 in these experiments could 
very well support the idea that PEX7 is completely released into the matrix of the 
organelle during the PTS2 import pathway, as previously suggested for the yeast 
peroxin (186). However, it is also possible that the sonication procedure used here 
leads to the extraction of proteins that are weakly associated with membranes and 
so, additional efforts were made to clarify if PEX7 is completely translocated into 
the organelle matrix or if, like PEX5, is retained at the DTM until the export step 
takes place. 
Considering that each rat liver peroxisome should contain hundreds of DTM 
complexes (see “Miscellaneous” in Experimental Procedures), we reasoned that it 
might be possible to co-import two PEX7 species, each of which was pre-
incubated with either an export-competent or -incompetent PEX5 protein, and 
determine how their export capacity is affected by the pre-incubation step. If the 
two proteins (PEX5 and PEX7) remain associated during their passage through 
the peroxisome, then the export capacity of a given PEX7 should be determined 
by the PEX5 protein with which it was pre-incubated. If, on the contrary, PEX7 
dissociates from DTM-embedded PEX5 and is indeed released to the organelle 
lumen, it is only reasonable to assume that PEX7 could be exported back to the 
cytosol through any one of the many DTMs available, and therefore, independently 
from whichever PEX5 was used during the pre-incubation step. 
 Such experiments would be feasible provided that 1) de novo formation of 
∆C1PEX5L-PEX7 complexes downstream of the pre-incubation step, i.e. during 
the import assay, are kept to a minimum and 2) the half-life of the ∆C1PEX5-PEX7 
interaction is relatively large so that PEX7 proteins pre-incubated with different 
recombinant PEX5 proteins do not exchange partners during the import assay. 
Figure 16 shows two sets of three chemically identical import reactions 
programmed with two versions of PEX7 that can be easily resolved by SDS-
PAGE, PEX7 and His-tagged PEX7 (lanes I1 and I2, respectively). The first set of 
reactions (lanes 1-3) contained standard amounts of recombinant p-PHYH and 
∆C1PEX5L (i.e., 500 ng and 100 ng, respectively) whereas in the second set 
(lanes 4-6) the amounts of both recombinant proteins were decreased 10-fold. The 
only difference between reactions in each set regards the way how radiolabeled 
PEX7 proteins and recombinant ∆C1PEX5L and p-PHYH were handled before 
starting the import reactions. In one assay the proteins were added to import 
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reactions individually, whereas in the other two import reactions one of the two 
35S-labeled PEX7 versions was pre-incubated with ∆C1PEX5L and p-PHYH 
before starting the assay. As shown in Figure 16, the total amounts of imported 
PEX7 proteins in each of the three reactions containing standard amounts of 
∆C1PEX5L and p-PHYH do not vary much (lanes 1-3), suggesting that the 
formation of trimeric complexes during the import assay is a relatively fast event 
under these conditions. Nevertheless, it is already apparent that pre-incubating a 
given PEX7 protein with the recombinant proteins provides some kinetic 
advantage to that PEX7 species in the subsequent import assay (compare lane 1 
with lanes 2 and 3), suggesting that the ∆C1PEX5L-PEX7 interaction is relatively 
stable. The kinetic advantage provided by the pre-incubation step becomes 
particularly evident in assays containing 10-fold less recombinant proteins 
(compare lane 4 with 5 and 6). Apparently, assembly of trimeric complexes during 
the import reaction becomes now a rate-limiting event.  
 
Figure 16. Co-import assays of 
35
S-His6PEX7 and 
35
S-PEX7. When PEX5L and p-PHYH 
are limiting, the pre-incubation step determines which PEX7 is efficiently imported.     
Two sets of three chemically identical co-import reactions were performed with the indicated 
amounts of ∆C1PEX5L and p-PHYH (lanes 1, 2, 3 and lanes 4, 5, 6, respectively). The 
recombinant proteins were either added individually (lanes 1 and 4) or they were pre-
incubated with one of the two reticulocyte lysates containing PEX7 (lanes 2, 5 and 3, 6 for 
35S-His6PEX7 and 
35S-PEX7 respectively) before being added to the co-import reaction also 
containing the other 35S-labeled PEX7 species. Import was allowed to occur for 5 min at 23 
ºC. Pronase-treated organelles were subjected to SDS-PAGE analysis and blotted onto a 
nitrocellulose membrane. Lanes I1 and I2, 2.5% of the reticulocyte lysates containing 
35S-
labeled His6PEX7 and PEX7 used in each reaction. 
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 It is important to note that under these conditions the concentration of 
recombinant ∆C1PEX5L is comparable to the one of endogenous rat liver PEX5 
(approximately 30 ng per reaction; (175)). This implies that any 35S-labeled PEX7 
that did not associate with ∆C1PEX5L during the pre-incubation step or, that 
having done so, dissociates from the recombinant protein during the import assay, 
may form a complex with endogenous PEX5 and, subsequently, be imported into 
and exported from peroxisomes. 
 Next, we performed import/export assays with the two 35S-labeled PEX7 
proteins, each of which was individually pre-incubated with recombinant p-PHYH 
and either ∆C1PEX5L or export-incompetent ∆C1PEX5L(C11A). As shown in 
Figure 17, when both PEX7 proteins were pre-incubated with ∆C1PEX5L(C11A), 
approximately 30% of each radiolabeled protein was exported after a 15-min 
incubation in the presence of ATP (upper panel, lanes 5 and 6; see also lower 
panel for a quantification of the data). As explained above, it is possible that 
endogenous rat PEX5 is more of an interfering factor in these assays than on 
those depicted in Figure 13 where the export efficiency in the presence of 
∆C1PEX5L(C11A) rated only at 15% (see Figure 13D). Importantly, when 
∆C1PEX5L was used in the pre-incubation step, the amounts of exported 35S-
labeled PEX7 proteins, be it His-tagged PEX7 (Figure 17, lanes 1 and 2) or 
untagged PEX7 (lanes 3 and 4), were now almost two-fold larger. Thus, the export 
competence of peroxisomal PEX7 is largely determined by the PEX5 protein with 
which it associated prior to import. This finding strongly suggests that the PEX5-
PEX7 interaction is preserved during the passage of this protein complex through 
the peroxisome and is only disrupted when PEX5 is exported back into the cytosol. 
These results strongly support a model in which at least a major fraction of PEX7 
enters and exits the peroxisome through the same DTM, suggesting therefore, that 
PEX7 is never released into the peroxisomal matrix (see Discussion).  
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Figure 17. Pre-incubation of PEX7 with export-competent or -incompetent PEX5 pre-
determines its export capability.    
Each reticulocyte lysate (35S-His6PEX7 or 
35S-PEX7) was pre-incubated individually with 25 
ng of p-PHYH and 5 ng of ∆C1PEX5L or ∆C1PEX5L(C11A) for 20 min at 23 ºC. These 
mixtures were added to a rat liver PNS in import buffer containing ATP in three different 
import configurations: (#1) Co-import of 35S-His6PEX7 and 
35S-PEX7 pre-incubated with 
∆C1PEX5L and ∆C1PEX5(C11A), respectively. (#2) Co-import of 35S-His6PEX7 and 
35S-
PEX7 pre-incubated with ∆C1PEX5(C11A) and ∆C1PEX5L, respectively. (#3) Co-import of 
35S-His6PEX7 and 
35S-PEX7, both pre-incubated with ∆C1PEX5(C11A). Import was allowed 
to occur for 5 min at 23 ºC. At this point, import was inhibited by the addition of NDPEX14 
(30 µM) and the reaction further incubated at 37 ºC. Aliquots were taken at the indicated time 
points. Pronase-treated organelles were subjected to SDS-PAGE analysis and blotted onto a 
nitrocellulose membrane. Autoradiograph and the corresponding Ponceau S-stained 
membrane are shown. Numbers to the left indicate the molecular masses of the protein 
standards in kDa. Lane I, 2.5% of the reticulocyte lysates containing 35S-PEX7 and 35S-
His6PEX7 were mixed and loaded together in the same lane. The bar graph shows averages 
and standard deviations (n=4) of the percentage of PEX7 export for the different co-import 
reactions. 
 
   IV- RESULTS 
63 
 
 
6. Export of PEX7 from the DTM does not require processing of the PTS2 
cargo it transport. 
  
 Previous work from Alencastre et al. revealed that PTS2 proteins are 
released to the peroxisomal matrix before PEX5 ubiquitination (198). The same 
conclusion was recently extended to PTS1 proteins (196). Interestingly, it has also 
been proposed that binding of PEX14 to cargo-loaded PEX5 triggers the release 
of PTS1 proteins into the lumen of the organelle (175). A priori, a similar 
mechanism could also be valid for PTS2 proteins. However, considering that PTS2 
proteins interact strongly with PEX7, and not with PEX5, and that the PTS2-
containing peptide is rapidly removed upon arrival of the precursor protein to the 
peroxisomal matrix, a different mechanism for the PTS2-cargo release is also 
possible. For instance, and as proposed recently (261), it might be that DTM-
bound PEX7 presents the PTS2 protein to Tysnd1, the PTS2-processing 
peptidase, and that cleavage of the signaling sequence leads to cargo release.  
To address this hypothesis, we checked if blocking PTS2 protein maturation 
would cause PEX7 to be retained at the DTM by impairing its recycling back to the 
cytosol. We first performed import assays with 35S-PEX7 and 35S-p-PHYH to 
compare the behaviors of wild-type p-PHYH with that of a mutant version where 
Pro29 and Thr30, the residues corresponding to the -2 and -1 sites of the 
proteolytic cleavage by Tysnd1 (262), were deleted (p-PHYH(∆29-30)). As shown 
in Figure 18, while both radiolabeled p-PHYH and p-PHYH(∆29-30) were 
efficiently imported to peroxisomes, only wild-type p-PHYH was processed into its 
mature form, as  predicted.        
 Interestingly, both versions of radiolabeled p-PHYH showed somewhat 
similar import kinectics, accumulating in peroxisomes during the 30 min import 
assay. 35S-PEX7 in contrast, accumulates much less, which is in agreement with 
its role as a cycling receptor. Of course, in this experimental configuration, the 
import of 35S-PEX7 and 35S-p-PHYH is uncoupled in the sense that 35S-PEX7 
reaches peroxisomes mostly carrying endogenous PTS2 proteins. Likewise, 35S-p-
PHYH(∆29-30) may be targeted to peroxisomes by endogenous PEX7. Therefore, 
the behavior of 35S-PEX7 in this experiment is not very informative. 
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Figure 18. 
35
S-p-PHYH and 
35
S-p-PHYH(∆29-30) are both imported to peroxisomes, but 
the ∆29-30 amino acid deletion effectively inhibits p-PHYH processing into its mature 
form (m-PHYH). 
A rat liver PNS was incubated with 35S-labeled PEX7 and either wild-type 35S-PHYH or the 
mutant 35S-p-PHYH(∆29-30) in import buffer containing ATP and recombinant ∆C1PEX5L. 
Import reactions were allowed to occur for 30 min at 37 ºC. Aliquots were taken at the 
indicated time points. Pronase-treated organelles were analyzed by SDS-PAGE and blotted 
onto a nitrocellulose membrane. Lanes I1 and I2, 5% of the reticulocyte lysates containing 
35S-PEX7 and 35S-p-PHYH or 35S-p-PHYH(∆29-30) used in each reaction, respectively. 
Autoradiograph (upper panel) and corresponding Ponceau S-stained membrane (lower 
panel) are shown. Numbers to the left indicate the molecular masses of the protein 
standards in kDa. 
 
 To really assess the effect that inhibiting the proteolytic cleavage of the 
PTS2 peptide might have on PEX7 import/export dynamics we performed in vitro 
export assays in the presence of recombinant p-PHYH(∆29-30), similar to those 
shown in Figure 13. The amount of recombinant PTS2 protein used in these 
assays (140 nM; see Experimental Procedures) ensures that the amount of 35S-
PEX7 reaching peroxisomes with endogenous PTS2 proteins is minimal as 
evidenced by both the stimulatory and inhibitory effects that recombinant p-PHYH 
has on 35S-PEX7 and 35S-thiolase import, respectively (see Figure 5). As shown in 
Figure 19, when recombinant wild-type p-PHYH is replaced by the mutant p-
PHYH(∆29-30), export of PEX7 back to the cytosol remains mostly unaffected. 
Thus, cleavage of PTS2-cargo proteins by Tysnd1 is not mandatory for PEX7 
export, suggesting that PTS2 protein maturation occurs after release of the 
precursors into the peroxisomal matrix. 
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Figure 19. Export of PEX7 is not affected when the PTS2- cargo protein it transports 
cannot be processed in the peroxisomal matrix. 
A- 35S-PEX7 was imported for 15 min in the presence of ubiquitin, ATP and the recombinant 
proteins ∆C1PEX5L and either p-PHYH (“Standard Reaction”) or p-PHYH(∆29-30) 
(“PHYH(∆29-30)”). The reaction mix was then diluted with ice-cold import buffer and the 
organelles were isolated by centrifugation and subjected to an export assay in the presence 
of ATP (see Experimental Procedures for details). Aliquots were collected at the indicated 
time points. Pronase-treated organelles were subjected to SDS-PAGE analysis and blotted 
onto a nitrocellulose membrane. Lanes I, 5% of the reticulocyte lysate containing 35S-PEX7 
used in each reaction. Autoradiograph (upper panel) and the corresponding Ponceau S-
stained membrane (lower panel) are shown. Numbers to the left indicate the molecular 
masses of the protein standards in kDa. B, The bar graph shows the average percentage of 
PEX7 export after 20 min under the conditions described in A. Standard deviations (n = 3) 
are also presented.  
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In this work we show that mammalian PEX7 is targeted to the peroxisome 
in a PEX5L- and PTS2-dependent manner where it acquires resistance to 
exogenously added proteases. Importantly, both PEX7 and pre-thiolase, a PTS2 
protein, reach this protease-protected location in a cytosolic ATP-independent 
manner ((198, 245) and this work), implying that the PEX7-PTS2 protein complex 
enters the peroxisome upstream of the first ATP-dependent step of the PEX5-
mediated protein import pathway, i.e., prior to monoubiquitination of DTM-
embedded PEX5. Additional data presented in this work corroborate this 
conclusion. As shown in Figures 7B and 10, a mutant version of PEX5 that cannot 
be monoubiquitinated at the DTM is as functional as the normal protein in 
promoting peroxisomal import of both PEX7 and pre-thiolase. Clearly, the PEX5-
mediated entry of both PEX7 and its cargo into the peroxisome is not linked to 
monoubiquitination of PEX5 at the DTM. Interestingly, this conclusion contrasts 
with the views of the so-called “export-driven import model”, a hypothetical 
mechanism recently proposed for the yeast PEX18/PEX7 system (213, 263). 
According to this model, monoubiquitination/export of PEX18, a member of the 
PEX20 family and a functional counterpart of PEX5 in the PTS2 protein import 
pathway, is mechanically linked to the translocation of PEX7, and presumably its 
cargo, across the peroxisomal membrane. Seemingly, the different architectures of 
the PTS2 protein import machineries in these organisms translate into at least 
some significant mechanistic differences.  
 
One of the aims of this work was to characterize the intraperoxisomal 
pathway followed by mammalian PEX7 during the PTS2 protein transport cycle. 
Up till now, there was only one study addressing this problem in a systematic 
manner. This is a work by Lazarow and colleagues describing the properties of a 
yeast PEX7-green-fluorescent-protein (GFP) fusion protein, a protein that although 
unable to complement the phenotype of a ∆PEX7 strain, accumulates massively in 
the peroxisomal matrix (186). As shown by those authors, cleavage of the fusion 
protein at the PEX7-GFP junction yielded a PEX7 protein that could now exit the 
organelle and rescue the phenotype of the ∆PEX7 strain. Apparently, there is a 
way out of the peroxisome for a PEX7 protein that was artificially accumulated in 
the matrix of the organelle. Based on those findings the authors proposed that 
PEX7 follows an “extended cycling mechanism”, i.e., that PEX7 enters completely 
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into the peroxisome matrix during the PTS2 protein transport cycle (186). The 
results described here for preL4R-PEX7 suggest that at least the N terminus of 
mammalian PEX7 enters sufficiently deep into the peroxisome matrix milieu to 
become accessible to the peroxisomal protease that cleaves the engineered pre-
sequence. Furthermore, fractionation of organelles by sonication did reveal the 
existence of a PEX7 pool displaying the properties expected for a peroxisomal 
matrix protein. Although these two observations are compatible with the “extended 
cycling” pathway (see Figure 20, pathway A), they do not allow us to formally 
exclude a model in which PEX7, like PEX5, is retained at the DTM during its 
passage through peroxisomes (Figure 20, pathway B). Indeed, sub-fractionation of 
organelles by sonication and centrifugation (the only experiment that would favor 
the “extended cycling mechanism” over the “retention” model) does have a major 
caveat: it can lead to the extraction of proteins that are weakly associated with 
membranes. In an attempt to clarify this important issue, we used our in vitro 
import/export system to determine whether the export competence of PEX7 is 
dictated by the export capacity of the PEX5 molecule that transported it to the 
peroxisome. If PEX7 is indeed released into the peroxisomal matrix, then it should 
be able to leave the organelle through any one of the hundreds of DTMs present in 
each peroxisome, regardless of the properties of the PEX5 molecule with which it 
associated in the cytosol. If on the contrary, PEX7 is retained at the DTM, its 
export efficiency will be defined by the PEX5 molecule that mediated its import. To 
assemble [PEX5-PEX7-PTS2] complexes of defined composition we pre-
incubated lysates containing the different 35S-labeled PEX7 with recombinant p-
PHYH and either the export competent or incompetent versions of recombinant 
∆C1PEX5L. These complexes were shown to be stable and efficiently imported to 
peroxisomes. The import/export experiments depicted in Figure 17 show that the 
PEX5 species used in the pre-incubation step (∆C1PEX5L or ∆C1PEX5L(C11A)) 
greatly determined the export efficiency of PEX7. In other words, when PEX7 is 
transported to the peroxisome by an export-competent PEX5 species, then PEX7 
becomes also export competent. In contrast, when PEX7 is transported to the 
organelle by an export-incompetent PEX5 molecule, then its subsequent export is 
also compromised. Although further data should be collected, these results 
strongly support a scenario where PEX7, traveling through the peroxisome, is 
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never released into the matrix and, like PEX5, is retained at the DTM until the 
extraction step (see pathway B in Figure 20).  
Figure 20. Working model for the PEX5-PEX7-mediated import pathway.  
After its assembly in the cytosol, the trimeric PEX5-PEX7-PTS2 protein complex docks at the 
docking/translocation machinery (DTM) [arrow 1]. This receptor-cargo complex then 
becomes inserted into the DTM [arrow 2]. This step culminates with the PTS2 cargo protein 
being delivered to the organelle matrix (where the PTS2 is cleaved) and PEX5 displaying a 
transmembrane topology (i.e., stage 2 PEX5). At this stage, PEX7 is completely protected 
from exogenous proteases exposing at least its N terminus to the peroxisome matrix. PEX7 
could be completely released from the DTM into the matrix milieu (pathway A) or may be 
retained at the DTM until the export step (pathway B). Following insertion into the DTM, 
PEX5 is monoubiquitinated at the conserved cysteine 11 residue [arrow 3], yielding stage 3 
PEX5. Monoubiquitination of PEX5 allows its ATP-dependent extraction from the DTM 
[arrow 4], and the subsequent export of PEX7 [arrow 5]. After deubiquitination of PEX5 
[arrow 6], the protein transport cycle restarts. 
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 Many important aspects of the PTS2-mediated protein import pathway 
remain unclear. One directly related to this work regards the molecular details of 
PEX7 export. Our data suggest that PEX7 leaves the peroxisomal compartment 
through the DTM site occupied by PEX5 and that peroxisomal PEX5 and PEX7 
probably exit the organelle separately. Our data clearly shows that PEX7 export 
from the peroxisome requires PEX5-free DTMs and therefore the action of the 
mechanoenzymes PEX1 and PEX6. Thus, these ATP-dependent enzymes surely 
influence PEX7 export, but whether this functional connection is merely indirect 
(i.e., via PEX5 export) or direct remains to be determined. Regardless, it is likely 
that the ATP-dependent extraction of PEX5 from the DTM also disrupts the 
interaction between PEX5 and PEX7, thus preparing PEX7 for a new PTS2-
recognition event.  
 
In this work we developed a strategy allowing us to analyze the trafficking of 
a PEX5L population engaged exclusively in the import of PTS2 proteins. The data 
collected suggest that PTS1- and PTS2-mediated import of mammalian 
peroxisomal matrix proteins are quite similar. First, it is now clear that the targeting 
of PEX5L to the peroxisomal membrane is in both cases cargo-dependent, be it a 
PTS1 cargo (202) or a [PTS2-PEX7] complex. Secondly, in both pathways, 
insertion of PEX5L into the DTM results in the exact same transmembrane 
topology for PEX5, with the protein exposing a 2-kDa fragment of its polypeptide 
chain to the proteases used in these in vitro import assays (see PEX5 stg2 in 
Figures 14 and 15). Finally, the receptors are recycled back into the cytosol in a 
process that depends on PEX5 monoubiquitination and extraction by the ATP-
dependent REM. The fast export kinetics we observe for monoubiquitinated 
PEX5L in our PTS2-only assays (see PEX5 stg3 in Figure 14B)  is also compatible 
with the kinetics previously observed in in vitro assays where PEX5L was working 
predominantly on the import of PTS1 proteins (199).  An aspect where PTS1 and 
PTS2 import might diverge regards the cargo release step. We have tried to 
implicate the proteolytic cleavage of the PTS2 pre-sequence as a possible trigger 
for PTS2-cargo release into the peroxisomal lumen. An association between these 
two events seemed likely. First, the relevance of PTS2 protein maturation is poorly 
understood as both the precursor and processed form of these enzymes appear to 
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be equally active (264, 265). Additionally, removing the targeting signal from the 
PTS2 protein would be an effective way to abrogate its interaction with PEX7, 
which in turn would result in its release into the peroxisomal matrix. In our attempts 
to clarify this issue, we used a mutated version of p-PHYH with a deleted cleavage 
site (p-PHYH(∆29-30)). Although this mutation effectively inhibited the proteolytic 
cleavage of the PTS2 pre-sequence, this protein showed a normal accumulation in 
peroxisomes and the export of PEX7 did not seem to be affected. Although we did 
not find evidence to suggest that PTS2 protein maturation triggers cargo release, 
or affects PEX7 recycling, we should note that the absence of Tysnd1 in mice 
does cause a phenotype that resembles that of a mild Zellweger spectrum 
disorder (261). Apparently, Tysnd1 contributes to a normal peroxisome function 
but, according to our results, its role is probably not linked to the biogenesis of the 
organelle. 
 Interestingly, very recent pull-down assays with Arabidopsis recombinant 
proteins showed that thiolase no longer interacts with PEX7 and PEX5 when 
PEX14 is added to the assays (266). This observation is comparable to the data 
previously described for human proteins showing that PEX14 disrupts PEX5-
catalase interaction (175). These results give strength to the notion that the 
interaction between PEX5 and DTM components (e.g. PEX14) is sufficient to 
trigger release of the cargoes into the peroxisomal matrix (156, 175, 196, 198, 
267). 
  
Although this work has clarified many aspects of the PTS2-mediated import 
pathway, it is clear that further work is necessary to completely understand many 
of the details of this machinery. As stated earlier, the direct action of the AAA 
ATPases PEX1 and PEX6 on PEX7 export cannot be formally excluded at the 
moment. Another question that we have yet to address regards the protein 
transport capacity of PEX5L. Can a single molecule of PEX5L simultaneously 
transport a PTS1 and a PTS2 protein to the peroxisome, or are these mutually 
exclusive events? While there have been studies where a tetrameric complex 
[PTS1-PEX5-PEX7-PTS2] was successfully assembled (266, 268), whether the 
docking/translocation machinery is capable to accommodate such complex and 
productively translocate both cargo-proteins remains to be verified. In this work, 
we developed an improved in vitro import system that can be used to further study 
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the PEX7-mediated import of PTS2 proteins and provide answers to these 
questions. This in vitro system will, in the near future, allow us to easily establish a 
correlation between PEX7 structure and function by studying the many mutations 
described in RCDP type 1 patients. For example, import assays using postnuclear 
supernatants from PEX7 knockout mice, together with other biochemical 
approaches (e.g., native-PAGE analyses, size-exclusion chromatography), will 
allow us to distinguish between defects in cargo-binding, PEX5 binding, DTM 
association and defects in the recycling step of the receptor. Such analysis could 
also lead to the identification of mutations that only affect PEX7 folding and 
stability. RCDP type I patients with this type of mutations could perhaps benefit 
from some form of chaperone therapy, an approach that has shown some promise 
when treating lysosomal storage diseases caused by the so-called chaperone-
responsive mutations (reviewed in (269, 270)). 
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